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Preface to “Viral Interactions with Host RNA Decay 
Pathways” 
Eukaryotes have evolved a wide variety of RNA decay pathways to maintain cellular homeostasis, 
carry out programs of gene expression, and respond to changing environmental conditions. Individual 
RNA turnover mechanisms can operate constitutively or under only particular cellular conditions; 
similarly, some target many RNAs, while others act with great specificity. It has become increasingly clear 
that there are extensive interactions between viruses and the host RNA decay machinery. Often, the 
cellular RNA decay machinery poses a threat to viral gene expression, but viruses can also manipulate 
RNA decay pathways to promote viral replication. This special issue focuses on how cellular RNA decay 
factors recognize and degrade viral RNAs and viral strategies to subvert or evade these pathways. 
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Abstract: All retroviruses use their full-length primary transcript as the major mRNA for Group-specific
antigen (Gag) capsid proteins. This results in a long 3′ untranslated region (UTR) downstream of the
termination codon. In the case of Rous sarcoma virus (RSV), there is a 7 kb 3′UTR downstream of
the gag terminator, containing the pol, env, and src genes. mRNAs containing long 3′UTRs, like those
with premature termination codons, are frequently recognized by the cellular nonsense-mediated
mRNA decay (NMD) machinery and targeted for degradation. To prevent this, RSV has evolved
an RNA stability element (RSE) in the RNA immediately downstream of the gag termination codon.
This 400-nt RNA sequence stabilizes premature termination codons (PTCs) in gag. It also stabilizes
globin mRNAs with long 3′UTRs, when placed downstream of the termination codon. It is not clear
how the RSE stabilizes the mRNA and prevents decay. We show here that the presence of RSE inhibits
deadenylation severely. In addition, the RSE also impairs decapping (DCP2) and 5′-3′ exonucleolytic
(XRN1) function in knockdown experiments in human cells.
Keywords: Rous sarcoma virus; RNA stability element; nonsense mediated decay; long 3′UTR;
deadenylation; decapping
1. Introduction
Retroviruses Have Aberrant mRNAs but Evade Cellular Nonsense-Mediated mRNA Decay
Retroviruses have compact genomes (<10 kilobases) that can code for eight or more viral proteins.
In order to maximize the coding potential, major unspliced retroviral mRNAs often possess features
such as long 3′ untranslated regions (UTRs), upstream open reading frames (uORFs), and retained
introns that are predicted to be targets of host cell RNA surveillance machineries [1–3]. The unspliced
RNA of Rous sarcoma virus (RSV), an avian retrovirus, carries a very long 3′UTR (ca. 7 kb); yet, it
is very stable. A cis-acting RNA sequence found in the RSV genome, designated the RNA stability
element (RSE; [4,5]) promotes viral evasion of the cellular nonsense-mediated mRNA decay NMD.
The RSE, a 400-nt element located immediately downstream of the gag termination codon in the
unspliced RSV viral RNA, has been shown to protect the viral RNA from Up-frameshift protein
1(UPF1) dependent decay in chicken cells [2,5–8]. Truncations in the RSE have defined a minimal RSE
element of 155 nts [8].
More recently, the RSV RSE has been shown to protect cellular mRNAs with long 3′UTRs from
NMD in mammalian cells [9]. Ge et al. inserted the RSE immediately downstream of the termination
codon in a β-globin NMD reporter with a long SMG5 3′UTR, and found that it promoted stability of
the reporter mRNA in human cells. Furthermore, the insertion of an antisense RSE fragment of similar
length into this construct failed to stabilize it. The RSE RNA was shown to bind polypyrimidine
tract binding protein 1 (PTBP1) and to decrease UPF1 association with the mRNA [9]. Interestingly,
hundreds of cellular mRNAs with long 3′UTRs seem to have a similar PTBP1-binding sequence
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downstream of the termination codon that stabilizes the mRNAs [9]. However, the mechanism of
mRNA stabilization by the RSE is unclear.
Degradation of NMD targets carrying premature termination codons (PTCs) has been shown to occur
through exonucleolytic and endonucleolytic decay pathways [10,11]. mRNA decay is a multistep process
regulated by several proteins. SMG6 has been shown to be important for endonucleolytic cleavage close to
the PTC in some mRNAs [11]. Exonucleolytic degradation usually starts with the removal of the poly(A)
tail (deadenylation). The deadenylated mRNA can then be decapped and subjected to 5′-3′ exonucleolytic
decay. It can also become a substrate for the 3′-5′ exonucleases [10]. Accelerated deadenylation has been
reported for PTC-containing NMD targets in mammalian cells [12,13]. However, the mechanism of decay
of long 3′UTR-containing NMD targets is less well studied.
In this study, we asked how NMD targets containing long 3′UTRs are degraded and how
the presence of the RSE allows them to evade NMD. We show that these NMD targets undergo
deadenylation and decapping, as well as 5′-3′ exonucleolytic decay. Further, the presence of the RSE
severely inhibits deadenylation and also impairs decapping and XRN1 mediated 5′-3′ exonucleolytic
decay of the NMD reporter containing a long 3′UTR.
2. Materials and Methods
2.1. Cell Culture and Transfections
HeLa Tet-off Advance cells (Clonetech, Mountain View, CA, USA) were maintained in Dulbecco’s
modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, 1X antibiotic-antimycotic
(Gibco 15240-062, Gaithersburg, MD, USA), and 0.3 mg/mL L-Glutamine (Life Technologies, Carlsbad,
CA, USA). Cells were transfected with desired constructs using FUGENE 6 transfection reagent
(Promega, Madison, WI, USA) according to the manufacturer’s protocol.
2.2. Analysis of Deadenylation and Decay
HeLa Tet-off Advance cells maintained in DMEM, supplemented with 10% fetal bovine serum (FBS)
and 5 ng/mL doxycycline (Sigma, St. Louis, MO, USA), were seeded at a density of 1 million cells in
10-cm plates. For each plate, 4.8 μg of the indicated pcTET2-reporter plasmid was co-transfected with
1.2 μg of the wild-type β-globin reporter (βwt) control plasmid using FUGENE 6 transfection reagent
(Promega) according to the manufacturer’s instructions. Twenty-four hours post-transfection, cells were
split into six equal aliquots in six-well plates. The next day, cells were washed twice with 2 mL 1X
Phosphate Buffered Saline (PBS) and incubated in medium without doxycycline for 5 h. Transcription
was shut off by adding doxycycline to a final concentration of 1 μg/mL, and cells were harvested in
Trizol (Life Technologies) after 30 min (time 0) and at the indicated intervals. Fifteen micrograms of
the total RNA were annealed to oligonucleotide OVB117 (5′-GAAAGTGATGCTTTAGTCTCAGTC-3′)
complementary to a sequence that is 214 nucleotides upstream of the poly(A) addition site of the reporter
mRNA to generate a shortened RNA form to measure poly(A) tail length. RNaseH/oligo treatment
of mRNA to generate poly(A) minus mRNA and measure deadenylation and decay were carried out
as described in Reference [14]. Gel mobility of the RNA bands were measured using the scale tool
on adobe Photoshop and sizes were determined by comparison of gel mobility to known size of the
various bands of the end labelled ladder used. Amount of DNA at each time point was quantitated
using densitometry and compared to a co-transfected control. mRNA levels from at least three biological
replicates performed using extracts from cells transfected separately were used in each experiment.
To detect mRNA levels in cells depleted for specific factors by RNA interference (RNAi) HeLa
Tet-off cells were depleted for the proteins using RNAi plasmids. HeLa tet-off cells were seeded at
0.2 million cells into 6-well plates and grown in DMEM supplemented with 10% FBS. After 24 h, each
well was transfected with 500 ng of the indicated pcTET2 reporter plasmid and 500 ng of RNAi plasmid
using Fugene 6 transfection reagent. Doxycycline was added to a final concentration of 5 ng/mL. Two
days post-transfection, the wells were washed with 1X PBS reagent twice and supplemented with
2
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media without doxycycline to turn on transcription of the reporter mRNA. Cells were collected in
Trizol after 12 h.
2.3. Northern Blotting
RNA was isolated using Trizol and resolved on 1.4% formaldehyde/agarose gels. 32P end-labeled
oligonucleotides (GGAGTGGCACCTTCCAGGGTCAAG) against bovine growth hormone (bGH)
polyadenylation signal present in both βwt and Tet-off reporter constructs were used for the detection
of mRNAs. Northern blots were imaged on Typhoon phosphor imager scanners and quantification
was performed using ImageQuant software (GE Healthcare Bio-Sciences Corp, Piscataway, NJ, USA).
3. Results
3.1. The RSV RSE Impairs mRNA Deadenylation
We have previously shown that the RSE can inhibit NMD of mRNAs with long 3′UTRs [5,9]. We
wanted to understand how the RSE affects the mechanism of decay. Since deadenylation is often the
first step in decay, we first studied the deadenylation rates of NMD reporters with long 3′UTRs in
the presence or absence of the RSE. To address this question, we conducted a transcriptional-pulse
chase experiment to determine the deadenylation and decay rates. Here, we used two reporter
constructs, WT-SMG5 and RSE-SMG5, under the control of a Tet-off promoter ([9], Figure 1). The
tetracycline (tet)-regulated reporter WT-SMG5 mRNA contains a β-globin mini-gene (with introns) and
the SMG5 3′UTR. The SMG5 3′UTR has been shown to trigger NMD; this is proposed to be due to its
length (1342 nt) [15–17]. The RSE-SMG5 construct carries a 400-nt RSE sequence inserted immediately
downstream of the stop codon, mimicking the natural context of the RSE in the RSV RNA.
WT-SMG5 mRNA
RSE-SMG5 mRNA





-globin SMG5  3’UTR
_AAAAAAAA
_AAAAAAAA
Figure 1. (A) Schematic of the Rous sarcoma virus (RSV) unspliced mRNA. The 400-nt RNA stability
element (RSE) (shown in green) is located immediately downstream of the gag stop codon. This RNA
has a very long 3′ untranslated region (UTR) of ca. 7 kb. (B) Schematic of tet-regulated β-globin
reporter mRNA constructs used in our studies. WT-SMG5 mRNA contains the β-globin sequence
followed by the SMG5 3′UTR sequence. The RSV RSE sequence was inserted into this reporter construct
immediately after the β-globin stop codon to generate RSE-SMG5.
These reporter constructs were co-transfected into HeLa tet-off cells (Clonetech, Mountain View,
CA, USA) with a vector constitutively expressing a control RNA. The expression of tet-regulated
mRNAs was induced for 5 h before transcription was shut off by the addition of doxycycline, and
3
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mRNA was collected at the indicated time points. The mRNAs were then subjected to oligo-dT
/RNaseH treatments followed by agarose Northern analysis to measure the poly(A) tail length and/or
decay over the time course (Figure 2). At the starting time, both constructs generated mRNAs with
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Figure 2. RNA stability element inhibits deadenylation. (A) Agarose northern blot showing
deadenylation and decay of WT-SMG5 and RSE-SMG5 mRNAs following tet-off transcriptional pulse
chase. RNA was subjected to oligonucleotide-directed RNaseH treatment prior to Northern blotting
for tail length determination. Lanes marked “dT” show the length of the RNA fragment without
a poly(A) tail; 1 kb plus DNA ladder (ThermoFisher Catalog number: 10787018, Halethorpe, MD,
USA) was end labelled and used for size determination (size corrected for RNA). Wildtype β-globin
(βwt) (upper band) was used as a loading control. (B) Poly(A) tail length determined from the gel
was plotted against time to show the initial and final tail length of the two reporter constructs. The
plotted values are the average of at least three separate experiments. Error bars show the standard
error. Deadenylation rate of the reporters were also determined from this analysis. (C) Deadenylation
and decay of the reporter mRNAs were compared by plotting mRNA remaining (% of original) and
poly(A) length remaining (% of original tail length) on the same plot.
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The WT-SMG5 reporter underwent rapid deadenylation at the rate of ca. 0.5 A/min, while the
RSE-SMG5 reporter showed deadenylation rates that slowed down to ca. 0.1 A/min (Figure 2B).
Deadenylation in mammalian cells usually proceeds in three steps. A slow initial deadenylation,
usually by the weaker deadenylase complex Pan 2/3, results in ca. 110-nt A tails. This is followed
by CCR4-NOT complex-mediated deadenylation resulting in a tail of ca. 22 As. In some cases, a
terminal deadenylation occurs where all the As are removed [12]. We observed that the deadenylation
of the RSE containing constructs did not surpass 70% of the original tail length in our 8-h time course.
In contrast, the WT-SMG5 mRNA deadenylated to a poly(A) tail of <50 nts in 8 h (Figure 2B,C).
We compared the deadenylation and decay rates of WT-SMG5 and RSE-SMG5 reporters
(Figure 2C). Transcripts containing only the SMG5 3′UTR exhibited a half-life of ca. 200 min while
the transcripts containing the RSE were substantially more stable (half-life > 480 min), confirming the
protective activity of the RSE in agreement with previous reports [9]. It is interesting to note that the
decay rates of each reporter construct closely mirrored their deadenylation rates. This would suggest
that the change in deadenylation is responsible for most of the alteration in decay.
3.2. Effects of the RSE on Decapping and 5′→3′ Exonucleolytic Decay
Nonsense mediated decay of mRNAs with long 3′UTRs could be exonucleolytic, initiating at
either or both mRNA ends, or endonucleolytic. We assessed the role of the RSE in the regulation of
decapping and 5′→3′ exonucleolytic decay. Decapping mRNA 2 (DCP2) or 5’-3’ Exoribonuclease
1 (XRN1) were depleted in HeLa-tet off cells using pSUPuro-Based RNAi plasmids previously
characterized in Eberle et al. (generous gift from Oliver Muhlemann) [11]. Knockdown was performed
by co-transfecting reporter constructs with pSUPuro-based RNAi plasmids against DCP2 or XRN1. We
then measured the accumulation of the reporter constructs at steady state. As a control, RNAi against
a scrambled sequence was separately carried out.
Upon depletion of the major decapping enzyme DCP2, we found the WT-SMG5 reporter construct
to be stabilized ca. 2-fold. The RSE-SMG5 construct was stabilized ca. 1.6-fold in this knockdown, as
compared to the corresponding scrambled controls. Depletion of XRN1, the major 5′-3′ exonuclease,
showed even greater accumulation of ca. 4.3-fold in WT-SMG5 and ca. 2.5-fold in RSE-SMG5 (Figure 3).
Thus, impairment of decay by down regulating DCP2 or XRN1 had less effect on the RSE-containing
construct than on the wildtype construct. This suggests the RSE is protecting the mRNA from
degradation at the 5′ end of the mRNA as well as at the 3′ end. We cannot tell from these experiments
whether the deadenylation precedes the decapping and 5′→3′ exonuclease activities.
We also noticed that XRN1 had a stronger effect on the accumulation of mRNA than DCP2 in
both WT-SMG5 and RSE-SMG5 constructs. Knockdown of XRN1 mRNA appears to be more robust
than DCP2 (Figure 3C). This could also be because there may be redundant decapping enzymes
present in the cell such as NUDT16 [18,19]. We also observed that DCP2 and XRN1 depletions led
to stabilizations of both reporter constructs. It is not surprising that the RSE-SMG5 reporter was
stabilized upon depletion of both DCP2 and XRN1, as both proteins are components of the general
decay pathway and are important for the decay of most normal messages. It should be noted that the
WT-SMG5 constructs were always more stabilized than the RSE-SMG5 in both knockdowns.
It has been previously reported that the depletion of XRN1 leads to the accumulation of a 3′
mRNA fragment for NMD targets that is generated by endonucleolytic cleavage [11]. We were unable
to detect the presence of 3′ fragments in our experiments. This would suggest that our NMD reporter
does not undergo decay via endonucleolytic cleavage. It is, of course, possible that endonucleolytic
cleavage is very sensitive to minor changes in conditions.
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Figure 3. Depletion of decapping mRNA 2 (DCP2) or 5′-3′ Exoribonuclease 1(XRN1) leads to the
accumulation of reporter mRNAs. (A) mRNA levels of the two reporters isolated from cells depleted
for Exoribonuclease 1 (XRN1 KD), decapping mRNA 2 (DCP2 KD), or scrambled control (scr) were
detected by agarose Northern blotting. NeoR, an mRNA produced from the same plasmid that
generates the tet-off β-globin constructs was used as a loading control. Mean numbers show the
amount of mRNA relative to scrambled control for WT-SMG5. SE shows the standard error of the
values. (B) Left panel shows levels of WT-SMG5 reporter in different knockdown conditions normalized
to the scrambled control. Right panel shows levels of RSE-SMG5 reporter in different knockdown
conditions normalized to the corresponding scrambled control. The plotted values are the average
of at least three separate experiments. Error bars show the standard error. (C) Quantitative reverse
transcription polymerase chain reaction (RT-PCR) was carried out to determine the levels of knockdown
of DCP2 and XRN1. Expression levels of these mRNAs were measured relative to the housekeeping
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Unpaired t-test was used to test for
significance of the change in expression between each knockdown and the corresponding scrambled
control. * denotes p-value < 0.05. ** p-value < 0.01.
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4. Discussion
mRNA degradation can be initiated by generating a new unprotected end vulnerable to attack
by an exonuclease. In human cells, unprotected ends can be generated by endonucleolytic cleavage,
deadenylation-dependent decapping, and exosome-mediated 3′-to-5′ decay. Deadenylation is one
of the slowest and often rate-limiting steps in degradation. In this study, we looked at how the RSE
protects long 3′UTR-containing mRNAs from NMD.
Our results show that the presence of the RSE severely inhibits deadenylation. We measured the
tail length of the WT globin-SMG5 reporter to be ca. 200 As. The deadenylation rates of this NMD
target mRNA was determined to be ca. 0.5 A/min. Both tail length and deadenylation rates are in
agreement with previous studies for PTC-containing globin NMD reporters [14]. In the presence of
the RSE, the WT-SMG5 reporter maintained the initial tail length of 200 As, but the deadenylation
rate slowed down to approximated 0.1 A/min. This five-fold change in deadenylation is a significant
impairment and could be a leading causal factor in the impairment of decay. It is also interesting to
note that the deadenylation of the WT-SMG5 reporter proceeds to <50 As. The length of the poly(A)
tail is known to affect translation and decay rates. mRNAs with short poly(A) tails (<50 A residues)
are generally translationally repressed (reviewed in [20]).
We compared the deadenylation and decay rates to estimate the contribution of deadenylation
to the degradation of the reporters. In both WT-SMG5 and RSE-SMG5, the decay rates follow the
deadenylation rates closely. This is different from the case for the PTC-containing β-globin reporter,
which undergoes rapid deadenylation but the decay rates seem to lag behind [13]. Our observation
suggests that deadenylation plays an important role in the degradation of long 3′UTR-containing
NMD targets and that the protective function of the RSE works through inhibiting deadenylation. How
the RSE regulates deadenylation remains an interesting open question. We have previously shown that
RSE can inhibit UPF1 binding to the RSE-SMG5 reporter mRNA. The UPF proteins, the SMG proteins,
and the eRF1-eRF3 complex constitute the SURF complex that is important for triggering NMD in
PTC-containing mRNA [21].
Nonsense mediated decay can be prevented by placing cytoplasmic poly(A) binding protein
(PABP) in proximity to the termination codon, suggesting that the increased distance between the
translation termination event and cytoplasmic PABP that results from termination at a PTC contributes
to NMD [11,16,22–24]. UPF1 has also been shown to play an important role in accelerated decay in
PTC-containing mRNAs [13]. This could be via interactions with SMG7 that has been shown to recruit
the CCR4-NOT deadenylation complex by directly binding to POP2, its catalytic subunit [25]. The RSE
could disrupt UPF1 binding, reducing SMG7 binding and hence the recruitment of the deadenylation
complex. It has been reported that the degradation activity of SMG7 involves the decapping enzyme
DCP2 and the 5′-to-3′ exonuclease XRN1 [25].
Using RNAi knockdown experiments, we show that the depletion of DCP2 and XRN1 results in
the enhanced steady-state accumulation of mRNA with both reporter constructs. This is not surprising,
as DCP2 and XRN1 are part of the general mRNA decay pathway. The effect of depletion of these
factors is more pronounced in the WT-SMG5 NMD reporter mRNA. Since deadenylation, decapping,
and XRN1 regulate the decay of the long 3′UTR-containing NMD target, we speculate that SMG7
might play an important role in the decay. Our results are in agreement with previous results with
other NMD substrates. Lejeune and Maquat have shown the importance of decapping and 5′-3′ decay,
as well as deadenylation, in the degradation of PTC-containing mRNA [10].
Given that poly(A) shortening is often the first and rate-limiting step in mRNA decay, viruses
likely have developed cis and trans acting factors to repress or circumvent deadenylation [26]. Several
families of RNA viruses, such as flaviviruses, bunyaviruses, and arenaviruses, have evolved 3′ terminal
stem loop structures to stabilize the RNA in the absence of poly(A) tails [27]. Poliovirus infection
promotes the degradation of poly(A) specific ribonuclease subunit 3 (PAN3), a protein that initiates the
deadenylation of many cellular mRNAs [28]. Sindbis virus recruits the cellular HuR protein to stability
elements in the 3′UTR of its transcripts to stabilize its poly(A) tail [29,30]. Kaposi’s sarcoma associated
7
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herpesvirus (KSHV) PAN RNA has a 79-nucleotide expression and nuclear retention element (ENE)
that forms a triple helix structure with the poly(A) tail that inhibits degradation [31]. Our results
using reporter constructs suggest that the Rous sarcoma virus RSE in its natural context functions
to prevent NMD by inhibiting deadenylation, and thus adds to the growing number of examples of
viruses manipulating deadenylation to escape cellular decay machinery.
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Abstract: Nonsense-mediated mRNA decay (NMD), a cellular RNA turnover pathway targeting
RNAs with features resulting in aberrant translation termination, has recently been found to restrict
the replication of positive-stranded RNA ((+)RNA) viruses. As for every other antiviral immune
system, there is also evidence of viruses interfering with and modulating NMD to their own advantage.
This review will discuss our current understanding of why and how NMD targets viral RNAs, and
elaborate counter-defense strategies viruses utilize to escape NMD.
Keywords: RNA quality control; gene expression; translation; RNA-protein interactions
1. Introduction
Virus Infections and Cellular mRNA Quality Controls
For their efficient replication, viruses rely on the host cell’s replicative machinery and must avoid
being recognized by cellular antiviral responses. Having co-evolved with their hosts for millions
of years, viruses have developed means to modulate cellular functions and redirect the metabolic
resources of the infected cell to their advantage. Antiviral defense mechanisms, on the other hand, have
arisen to counteract pathogen infections. Recent evidence indicates that cellular RNA quality control
systems, such as the nonsense-mediated mRNA decay (NMD) pathway, can restrict viral infections by
different mechanisms [1,2], suggesting that the cellular RNA decay machinery could act as an ancestral
form of intrinsic antiviral immunity [3]. Supporting this hypothesis, there is increasing evidence that
viruses have evolved mechanisms to interfere with or modulate NMD at different post-entry stages of
their replication cycle. In this review, we will analyze current evidence that supports a role of NMD
in counteracting virus infections. To set the stage, we first describe the known features that make a
cellular mRNA a substrate for NMD. Next, we apply this knowledge on viral RNAs and discuss how
viral mRNAs could be recognized and attacked by the NMD surveillance machinery. Additionally, we
will discuss which counter-defense strategies viruses utilize to ensure stability of their transcripts.
2. The Nonsense-Mediated mRNA Decay (NMD) Pathway
Eukaryotic cells possess numerous RNA quality control systems that degrade faulty mRNAs and
so prevent the production of aberrant proteins. These mechanisms, including the NMD, the non-stop
mRNA decay (NSD), and the no-go decay (NGD) pathways, are important for dynamically shaping
the transcriptome and the proteome of eukaryotic cells to variable physiological conditions [1].
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Of these mechanisms, NMD is arguably the best characterized [2]. NMD modulates the RNA levels of
about 10% of all genes in diverse eukaryotes [3,4].
NMD was originally identified as an mRNA degradation pathway targeting transcripts that
harbor a premature termination codon (PTC) [5–7]. However, in the last decade, it has become clear
that NMD targets include a much broader number of substrates with different features. Transcripts
targeted by NMD include those with PTCs in an internal exon or sometimes also in the terminal exon,
as well as transcripts with long 3’-untranslated regions (UTRs), introns downstream a termination
codon (TC) or upstream open reading frames (uORFs; Figure 1) [8–11]. The molecular details of how
NMD is regulated and how NMD factors are recruited to target transcripts are not yet fully understood.
It is clear that translation is a prerequisite for NMD and converging evidence suggests that a failure to
terminate translation correctly triggers NMD [2]. This implies that any RNA molecule that engages
with ribosomes to undergo translation is a potential target for NMD, including viral RNAs.
AAA
B PTC in internal exon
AAA




E Normal TC and 3 UTR intron
AAA
F Normal TC and long 3 UTR
Different types of cellular NMD substrates
AAA
A Normal TC
Figure 1. Different types of cellular mRNAs that can be substrates for nonsense-mediated mRNA decay
(NMD). (A) An mRNA with a normal termination codon (TC) positioned in a context that does not
trigger NMD: the termination codon is at the end of the last exon followed by a short 3’-untranslated
region (3’-UTR). (B–F) NMD targets comprise mRNAs with a truncated ORF due to a premature
termination codon (PTC) in an internal (B) or terminal (C) exon. The presence of protein complexes
known as exon junction complexes (EJCs) downstream the TC increases, but it is not necessary for,
NMD (see Section 3). Upstream ORF (uORF), (D), the presence of EJC-associated introns in the 3’-UTR
(E), and long 3’-UTR (F), all act as RNA destabilizing factors and trigger NMD. White boxes denote
translated ORFs; gray boxes denote the fraction of the ORF that is not translated due to the presence of
a PTC. Ribosomes are indicated in black, EJC in purple.
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3. NMD Factors
As detailed in several recent reviews, the activation of NMD requires a set of evolutionarily
conserved core regulatory factors called up-frameshift (UPF) 1 to 3 and additional factors in
metazoans [2,11–13].
UPF1 is a monomeric superfamily 1 (SF1) helicase that is essential for substrate recognition and
NMD execution. The helicase domain consists of two RecA domains that bind single-stranded RNA
(ssRNA) and DNA (ssDNA). It is flanked by an N-terminal cysteine and histidine rich (CH) domain
that binds UPF2 [14], the ribosomal protein RPS26 [15] and the decapping enzyme subunit DCP2 [16],
and by an unstructured C-terminal domain enriched in serine-glutamine (SQ) dipeptides.
UPF2, the second conserved NMD factor, functions as a scaffold linking UPF1 and UPF3. Human
UPF2 has three tandem MIF4G domains and a C-terminal UPF1 binding region. MIF4G-3 interacts
with UPF3 while the specific functions of MIF4G-1 and MIF4G-2 are unknown [17]. Besides bridging
UPF1 with UPF3, UPF2 functions as an activator of UPF1 by promoting its helicase activity, thereby
switching UPF1 from the RNA clamping to the RNA unwinding mode [18].
Of the three UPF proteins, UPF3 is the least conserved one [7]. Two UPF3 versions encoded by
two different genes exist in mammals, UPF3A and UPF3B. Both are predominantly nuclear and shuttle
between the nucleus and the cytoplasm. They are associated with spliced mRNA and bind UPF2
and the exon junction complex (EJC) [19], a multi protein complex comprising four core components
(eIF4A1, MAGOH, Y14 and MLN51) and more than a dozen other factors [20], which upon splicing
assembles 24 nucleotides upstream of the spliced junction and remains associated with the mRNA
until translation, thereby “marking” the exon-exon junction.
Tethering experiments showed that UPF3A is less active than UPF3B in promoting NMD [21].
In human cells, UPF3B is the predominantly expressed protein and UPF3A becomes specifically
upregulated if UPF3B levels are experimentally decreased or low because of a mutation [22].
Interestingly, a recent study shows that UPF3A is critical for spermatogenesis and provides evidence
that it can antagonize NMD by sequestering UPF2, while its paralog, UPF3B activates NMD [23].
In addition to the three UPF factors, activation of NMD in metazoans requires the function of
several additional proteins, among them a set of proteins originally identified in Caenorhabditis elegans
known as the “suppressor with morphogenetic defects in genitalia” (SMG), SMG1 and SMG 5–9. These
proteins control the phosphorylation and de-phosphorylation of UPF1 and trigger mRNA degradation
by recruiting specific mRNA decay activities.
SMG1 belongs to the phosphatidylinositol 3 kinase-related protein kinase (PIKK) super family
and it is responsible for phosphorylation of UPF1 at multiple S/TQ motifs [24]. SMG1, SMG8 and
SMG9 form together with hypophosphorylated UPF1 and the eukaryotic release factors (eRF) 1 and 3 a
complex called SURF [25,26], in which SMG8 and SMG9 repress the kinase activity of SMG1 [27]. Upon
dissociation of SMG8 and SMG9 from SMG1, UPF2 mediates a structural rearrangement between
SMG1 and UPF1 that activates the kinase, leading to UPF1 phosphorylation [28].
SMG5, SMG6 and SMG7 interact preferentially with hyperphosphorylated UPF1 and hence
function further downstream in the NMD pathway. SMG5 and SMG7 form a heterodimer which
interacts with phosphorylated SQ motifs in the C-terminal part of UPF1 and which recruits the
CCR4-NOT deadenylase complex onto the mRNA [29,30]. SMG6 by contrast appears to function
as a monomer [31]. Its C-terminal PIN domain has endonuclease activity [32] and it interacts
with UPF1 through phosphorylated T28 as well as phosphorylation-independent contacts in the
helicase domain [33,34]. In addition to the abovementioned NMD factors, additional proteins have
more recently been shown to be involved in NMD and their molecular function is currently being
investigated [25,35–37].
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4. Current NMD Model
Aberrant Translation Termination Activates NMD
During normal translation termination, the ribosome when arriving at a termination codon (TC)
binds eRF1 and eRF3. eRF1 recognizes the TC in the A-site of the stalling ribosome and forms a complex
with the GTPase eRF3 to catalyze peptide release [38]. After eRF3-mediated GTP hydrolysis, eRF1
interacts with the ATP-binding cassette subunit family E member 1 (ABCE1). This interaction induces
a structural change that stimulates ATP hydrolysis and leads to the separation of the two ribosomal
subunits and the mRNA [39,40]. Importantly, in the context of NMD, the cytoplasmic polyA binding
protein 1 (PABPC1) has recently been shown to enhance the recruitment of the eRFs, thereby stimulating
correct and efficient translation termination [41]. Most likely due to this translation termination
promoting activity, PABPC1 can potently antagonize NMD [42,43]. Based on these observations, it was
postulated that whether an mRNA is subjected to NMD mainly depends on a competition between
UPF1 and PABPC1 for binding to eRF3 [44]. The outcome of this competition is predicted to depend on
the location of UPF1 and PABPC1 binding sites relative to the TC. Consistent with this model, TCs
located in an mRNA towards the 3’ end in the vicinity of the polyA tail (i.e., PABPC1 binding sites) will
usually not elicit NMD. In contrast, PTCs, which can occur anywhere in the mRNA, as well as long 3’
UTRs may allow UPF1 rather than PABPC1 to interact with eRF3 at the terminating ribosome and as a
consequence activate NMD by formation of the SURF complex and subsequent UPF1 phosphorylation.
Alternatively, if a TC is located more than 50 nucleotides upstream of the final exon–exon junction
on the mRNA, an EJC most likely remains bound at this exon-exon junction, a constellation that is
well known to activate NMD [45]. It is thought that in this situation the EJC-bound UPF3B, via UPF2,
recruits UPF1 and promotes SURF complex formation and NMD activation.
The observation that ribosomes reside longer at TCs on transcripts subject to NMD [46,47]
indicates that NMD-triggering translation termination is mechanistically distinct from proper
termination. However, the mechanistic differences between proper and NMD-triggering termination
have remained elusive so far.
After formation of the SURF complex on an NMD targeted mRNA and subsequent SMG1-mediated
phosphorylation of UPF1, RNA degradation can be induced in several different ways in mammals by the
recruitment of the endonuclease SMG6, the SMG5-SMG7 heterodimer, and/or the decapping enhancer
proline-rich nuclear receptor co-activator 2 (PNRC2) to phosphorylated UPF1. SMG6 cleaves the mRNA
endonucleolytically near the terminating ribosome [32,48,49], while the SMG5/SMG7 heterodimer
recruits the CCR4–NOT deadenylase complex, which catalyzes polyA tail shortening and eventually
stimulates decapping of the RNA by the decapping complex [30]. A third possibility to induce RNA
decay consists in the direct recruitment of the decapping complex by UPF1, either directly or indirectly
in a PNRC2-dependent manner [50–53].
Finally, hydrolysis of the UPF1-bound ATP promotes the release of the NMD factors from the
degrading mRNA [54], and concomitantly UPF1 is dephosphorylated by protein phosphatase 2A
(PP2A) in a process that seems to require SMG5, SMG6 and SMG7 [55,56].
Thus, in a nutshell, this model proposes that correct translation termination requires the TC to
be positioned in the messenger ribonucleoprotein (mRNP) spatially close to termination stimulating
factors, such as for example PABPC1, whereas aberrant translation termination would be characterized
by the absence of these factors and/or the presence of decay stimulating factors, such as for example
UPF1 [2]. From the virus perspective, this general rule can be exploited. As discussed below, viruses
have evolved a plethora of strategies to interfere with or utilize NMD to their advantage.
5. Viral mRNAs as Substrates for NMD
During evolution, the replication strategy as well as the selective pressure to maximize the coding
capacity of a viral RNA (vRNA) without increasing its genome size has introduced features in vRNAs
that could make it a substrate for NMD. In particular, the presence of multiple ORFs on the same RNA
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makes many of the TCs in vRNAs appear in positions where one would expect them to elicit NMD.
Some of the viral ORFs resemble uORFs and many TCs occur in the middle of the transcript far away
from a polyA tail. Figure 2 depicts a series of viral mRNAs that contain bona fide signatures of NMD
recognition (compare Figure 2 with Figure 1). However, vRNAs flourish in the nucleus and cytoplasm
of infected cells, suggesting that viruses employ mechanisms that protect their transcripts from the
host cell’s degradation pathways.
Figure 2. Different types of viral mRNAs that can be substrates for NMD. Similar to aberrant or
unconventional cellular mRNA, viral transcripts contain features that make them susceptible to NMD,
including the presence of PTC and long 3’-UTRs (A); the absence of cap-structure and polyA (B); uORFs
(C); and a combination of all such as in the case of retroviruses RNAs, the translation of which also
includes ribosomal frameshifts (D). In the case of Rous sarcoma virus (RSV), RNA secondary structures
immediately downstream of the TC can act as RNA Stability Elements (RSE; D).
6. Documented Role of NMD and NMD Factors in Virus Infection
To date, a role for NMD or NMD factors in virus infection has been demonstrated for
positive-stranded RNA ((+)RNA) viruses of animals (alphaviruses and hepatitis C virus) and
plants (Alphaflexiviridae and Tombusviridae) [57,58], and for retroviruses (Rous Sarcoma virus, human
T-lymphotropic virus type 1, and human immunodeficiency virus (HIV)) [59,60]. As illustrated in
Figure 2 and discussed below, the mRNAs produced by each of these viruses contain features known
to trigger NMD. In few cases, a viral counter-defense mechanism has been identified that protects the
viral mRNA from NMD.
6.1. Positive-Stranded RNA ((+)RNA) Viruses
6.1.1. Alphaviruses and Plant (+)RNA Viruses
Recent studies have shown that NMD might constitute a conserved arm of the intrinsic innate
immunity that is able to recognize and degrade vRNAs in extant eukaryotes, including mammalian
cells, insects and plants [57,58,61]. Genome-wide small interfering RNA (siRNA) screens carried out
in mammalian cells identified UPF1, SMG5 and SMG7 as host factors that restrict the replication of
Semliki Forest virus (SFV) and Sindbis virus (SINV), two alphaviruses of the Togaviridae family [57].
14
Viruses 2017, 9, 24
Follow-up studies in cells infected with replication-incompetent viruses showed that depletion of
UPF1 increased the half-life of the SFV genomic RNA (gRNA), indicating that this RNA is a substrate
for NMD [57,62].
As for all (+)RNA viruses, the genome of alphaviruses is an mRNA-like molecule that once
released into the cytoplasm of infected cells is immediately translated (Figure 3). The alphavirus
genome contains two ORFs. The upstream ORF encodes the nonstructural proteins responsible for
genome RNA replication and transcription. The second ORF encodes the structural proteins, capsid
and envelope, that are required for the assembly of new virions (Figure 3A). Translation of the second
ORF requires the synthesis of a sub-genomic mRNA encoded in the 3′ third of the genome. This
configuration creates a very long 3′ UTR (about 4000 nucleotides) during the translation of the first
ORF from the full-length gRNA (Figure 3B), which could increase susceptibility to NMD. Surprisingly
however, substantial shortening of the 3′ UTR failed to relieve the gRNA from the repressive effect of
UPF1. Thus, it is currently not known what renders the genome of alphaviruses susceptible to NMD.
In addition to the length of the 3′ UTR, other factors could render the viral mRNA genome a target
of NMD. Translation termination is a crucial moment for NMD activation (see Section 4). As for all
other (+)RNA viruses, the replication of Alphavirus genomes requires the synthesis of a full-length
complementary RNA strand (referred to as the negative-sense RNA ((-)RNA)). The viral replication
complexes, encoded by the first ORF, synthesize (-)RNA in 3′-to-5′ direction of the gRNA (Figure 3C).
Translating ribosomes, however, move along the same RNA molecule in 5′-to-3′ direction, opposite to
the viral polymerase complex. This begs the question how the viral polymerase can copy the RNA
genome, if the same molecule is used by ribosomes that move in opposite direction? A mechanism
must exist to clear translating ribosomes from the vRNA template. The molecular details of this process
are not clear. According to current models, the newly synthesized viral replicase proteins could bind
to both vRNA and components of the translation machinery to trigger translation termination (or
block translation re-initiation). This could create a RNP environment that triggers NMD activation.
Consistent with this model, Balistreri et al. showed that impairing the helicase activity of the viral
replicase complex rendered SFV hypersensitive to UPF1 depletion, which increased virus replication
in primary human cells up to 20-fold [57,63]. More studies are required to shed light on this important
aspect of virus replication.
In an independent study, the role of UPF1 as a restriction factor for SINV was confirmed in vivo
in insects, using Drosophila as a model system [61]. In this study, the two ORFs of SINV were separately
inserted into the cellular genome of the insect cells and the transcription of the viral RNAs was
launched by an inducible promoter. In this system, inhibition of the RNA interference (RNAi) pathway
provided a first means to increase virus production. In addition, expression of a dominant negative
form of UPF1 increased the yields of released viruses by more than three-fold. These results are in
agreement with those obtained in mammalian cells and collectively indicate that something in the
genome of alphaviruses, or in the mode of translation termination, renders these RNA molecules
susceptible to UPF1-mediated restriction.
In addition to alphaviruses, antiviral effects of NMD have also been shown for (+)RNA viruses of
plants [58]. Starting from a genetic screen in Arabidopsis, this study identified UPF1, UPF3 and SMG7 as
restriction factors for (+)RNA viruses of the Alphaflexiviridae and Tombusviridae. Similar to alphaviruses,
these viruses also have mRNA genomes with long 3′ UTRs due to the presence of multiple ORFs
encoded by subgenomic RNAs. Unlike the results obtained for SFV in animal cells, however, Garcia
and colleagues showed that shortening the 3′ UTR of the corresponding viral transcript did increase
vRNA accumulation in infected cells and resulted in more efficient virus spread. Thus, for these
particular viruses, the length of the gRNA 3′ UTR is an important determinant for their susceptibility
to NMD. Supporting this notion, the authors showed that a (+)RNA virus of the Potiviridae family with
a single ORF and a short 3′ UTR was not restricted by the NMD.
15
Viruses 2017, 9, 24
Figure 3. The replication cycle of a positive-stranded RNA ((+)RNA virus). (A) The bi-cystronic mRNA
genome of Alphaviruses is capped a poly-adenylated. The first ORF encodes the replicase proteins;
the second ORF encodes the structural genes (capsid and envelope proteins). (B) After virus entry, the
genome is delivered into the cytoplasm where the first ORF is translated, leaving a ≈4000 nucleotides
long 3’-UTR. (C) Newly synthesized viral replicase polyproteins assemble at the 3’-end of the genome
and produce a complementary “minus” sense copy. Translation of the viral genome must be shut down.
(D) After auto-proteolytic cleavage, the replicase complex switches the template and uses the “minus”
strand to synthetize new copies of full-length genome and a shorter sub-genomic mRNA that encodes
the structural proteins (the second ORF).
6.1.2. Hepatitis C Virus (HCV)
Recent studies have shown that approximately 3%–10% of the transcriptome is affected by NMD
directly or indirectly in diverse eukaryotes [10]. Thus, virus induced global inhibition of the NMD
pathway could lead to major rewiring of the cell, a strategy that viruses could use to create an
environment favorable for virus infection. Recent evidence suggests that this could be the case for
hepatitis C virus (HCV), a leading cause of liver disease. Using hepatoma cell lines, Ramage and
co-authors showed that HCV infection causes a progressive inhibition of NMD activity as measured by
the accumulation of three cellular RNAs known to be NMD substrates (SC35, ASNS and CARS) [64].
A combination of proteomics and RNAi-screening approaches revealed that the viral protein “core”
binds to the EJC recycling factor WIBG/PYM and prevents its interaction with other components of
the EJC (Y14 and Magoh). Depletions of WIBG/PYM decreased HCV replication and concomitantly
suppressed the accumulation of NMD substrates. The mechanisms by which EJC components and
NMD inhibition influence HCV replication remains unclear. Like other (+)RNA viruses that infect
mammals, HCV is a cytoplasmic virus. Viral RNAs never reach the nucleus and do not contain introns.
The inhibition of NMD observed upon HCV infection could result in the stabilization of multiple
cellular mRNAs. This could contribute to creating an environment favorable to virus replication and
could contribute to pathological effects associated with HCV infection [64]. Future studies are needed
to shed more light into this process.
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6.2. Retroviruses
6.2.1. Rous Sarcoma Virus (RSV)
Once transcribed from its integrated DNA, the full length unspliced transcript of Rous sarcoma
virus (RSV) consists of a single mRNA molecule that contains several ORFs (Figure 2D). Although
ribosomes translating the first ORF, gag, terminate about 7000 nucleotides upstream of the polyA tail
and could therefore be expected to activate NMD, the unspliced full length viral RNA is surprisingly
resistant to NMD [65]. However, PTCs experimentally introduced into different places of the gag
ORF were shown to trigger NMD in chicken cells, suggesting that the natural TC of the gag ORF may
be protected from activating NMD by specific cis-acting signals [65,66]. Indeed, it was found that
this NMD resistance is conferred by a 400 nucleotides long sequence element located immediately
downstream of gag TC that was termed the RNA stability element (RSE, Figure 2D) [67,68]. The RSE
forms a complex RNA secondary structure [69] and includes several pyrimidine-rich stretches that
were recently shown to serve as the binding platform for the polypyrimidine tract binding protein 1
(PTBP1). Recruitment of PTBP1 to the proximity of a termination codon prevents the recruitment of
UPF1 and thereby antagonizes NMD, leading to the stabilization of RSV full length RNA and reporter
transcripts [70]. The pyrimidine-rich sites are essential for RNA stabilization as mutations at these
sites abolished protections of both viral and reporter mRNAs [70]. The authors of this study further
showed that the role of PTBP1 as an NMD antagonizing factor is not limited to viral RNAs but that it
can also efficiently protect cellular mRNAs from NMD when recruited downstream of an otherwise
NMD-triggering TC.
6.2.2. Human T-lymphotropic Virus Type 1 (HTLV-1)
Stabilization elements such as the RSE of RSV act in cis to protect the mRNA molecule that harbors
them. As an alternative strategy, two proteins from another retrovirus, human T-lymphotropic virus
type 1 (HTLV-1), have been shown to bind to core components of the NMD machinery, causing a
global inhibition of the NMD pathway. In one study, the protein TAX was shown to bind UPF1 and the
translation initiation complex component INT6/eIF3E, which resulted in partial inhibition of NMD
and the stabilization of viral transcripts [71]. A second study reported that the viral protein REX had
similar function and was even more efficient than TAX in inhibiting NMD [72]. In this scenario, the
viral proteins act in trans to inhibit NMD and in turn increase the half-life of viral mRNAs.
6.2.3. Human Immunodeficiency Virus Type 1 (HIV-1)
In the tug-of-war between pathogens and their host defense mechanisms, viruses often
evolve means to subvert the function of cellular factors to their advantage. In the case of human
immunodeficiency virus type 1 (HIV-1) for instance, two groups have shown that rather than restricting
infection, UPF1 is a positive regulator of virus gene translation, vRNA nuclear export, and specific
infectivity of released virions [73–75]. One of the groups reported an association and co-localization of
UPF1 with the viral structural protein Gag during virus replication [73]. Depletion of UPF1 caused a
reduction of the HIV-1 RNA and protein pr55Gag and UPF1 overexpression led to an up-regulation of
HIV-1 expression. These UPF1-mediated effects required ongoing translation and the ATPase activity
of UPF1 but not the interaction with UPF2 [73]. Interestingly, overexpression of UPF1 mutants that
are inactive in NMD were still found to increase HIV-1 gene expression, suggesting a mechanism
that requires the ATPase activity of the cellular enzyme but that is different from the canonical role
of UPF1 in NMD. A follow-up study documented the presence of UPF1 in two distinct viral RNPs
during the late replication phase [74]. One of them was detected in the cytoplasm and contained UPF1
and the viral protein Gag. The second RNP, containing UPF1, Rev, CRM+, DDX3, the nucleoporin p62,
and the short isoform of UPF3a (UPF3aS), was shown to promote nucleo-cytoplasmic export of the
vRNA. Interestingly, while the interaction between these RNP components and UPF1 was necessary
for nuclear export of the viral genome, UPF2 and the long isoform of UPF3a (UPF3aL) were excluded
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from this complex. UPF2 was a negative regulator of HIV-1 RNA nuclear export. Unlike UPF3aS,
UPF3L binds UPF2 and overexpression of UPF3aL also repressed the nucleus-cytoplasmic transport of
the unspliced vRNA [74]. In this elegant work, the authors propose a model in which the viral protein
Rev might bind UPF1 and compete for the binding of UPF2, thereby excluding this negative regulator
(and its partner UPF3aL) from the viral RNP in the nucleus and promoting nuclear export of the HIV-1
RNA genome. This model implies that the overexpression of UPF2 and similar negative regulators of
vRNA nuclear export could be used in conjunction with other approaches as a therapeutic strategy to
interfere with HIV-1 replication [74].
Along the same lines, Serquina and colleagues confirmed that UPF1 is a positive regulator of HIV-1
infection, while the NMD-cofactor UPF2 had no role [75]. Following proteomic studies, the authors
found that HIV-1 virions contain UPF1 and that viruses produced from UPF1-depleted cells are much
less infectious. The loss of infectivity was not due to differences in the structure of released viruses,
which contained normal ratios of genomic RNAs and correctly processed structural components.
Instead, the authors found that the lack of UPF1 from virus-producing cells resulted in released virions
that had impaired reverse-transcription during the following round of infection. Interestingly, the
ATPase activity of UPF1 was not necessary for this step. Thus, the positive role of UPF1 on HIV-1
RNA nuclear export and translation is ATPase dependent [74], whereas the UPF1-induced increased
efficiency of reverse-transcription in newly infected cells is ATPase independent [75].
In cells lacking UPF1 or expressing ATPase-defective UPF1 mutants, the infectivity of HIV-1
virions was impaired [75]. These results indicate a role of UPF1’s helicase activity during virion
assembly and release. The results of the two groups differ in that Serquina and colleagues did not
detect an increased HIV-1 expression upon exogenous UPF1 overexpression. A possible explanation
for the discrepancy between the results is that the two groups monitored different readouts and that
the experiments were performed in different cells, which are known to have difference susceptibility
to UPF1 depletion.
7. Conclusions and Outlook
Thus far, NMD has been viewed as a cellular process that regulates stability of certain types of
aberrant mRNAs. Given the recent findings indicating an antiviral role of NMD, it has been speculated
that the detection of pathogenic RNAs might have been the selective advantage driving the evolution
of NMD rather than quality control of cellular mRNAs [76].
Regardless of its origin, the fact that viral genomes can be detected by NMD and that viral
proteins have evolved to counteract/exploit NMD suggest that this pathway plays an important role
during virus infection. Viruses will therefore become valuable tools for dissecting how NMD factors
interact with and are activated by RNA substrates. Conventional tools, such as plasmid-based reporter
constructs and inducible systems, provide RNA molecules that are produced in the nucleus and are
therefore influenced by nuclear RNA processing and quality control mechanisms. One of the great
advantages of using viruses as a tool to investigate NMD is that for many of them (e.g., (+)RNA
viruses), the genome is delivered directly into the cytoplasm of the infected cells without undergoing
nuclear quality control. This provides the unique opportunity to study specifically the cytoplasmic
events of NMD without separated from any effects on RNA stability originating from splicing, nuclear
export and RNA editing. Moreover, identification of viral factors that interfere with NMD and the
characterization of the molecular mechanisms of this processes will shed new light onto different steps
of the NMD mechanism, such as substrate recognition, UPF1 activation and mRNA degradation.
An important question to be addressed in the future is what triggers NMD in viral RNAs.
Although many viral transcripts contain signatures known to activate NMD, a prediction cannot
always be made based on the knowledge of known cellular NMD targets. In the case of alphaviruses
for instance, the truncation of most of the long 3′ UTR from the viral genome did not relieve the virus
from being suppressed by UPF1 [57]. This unexpected result implies that in addition to 3′ UTR length,
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translation termination of the viral first ORF is aberrant for another reason than the distance to the
polyA tail. Future work will hopefully clarify these issues.
In addition to the NMD core components, different viruses have been recently described to
specifically inhibit or degrade cellular factors involved in RNA degradation [62], which supports a
general antiviral role for the cellular RNA turnover systems and indicates that in the absence of viral
counter-defense strategies, viral mRNAs would become detectable and vulnerable to these quality
control pathways. Understanding how cells recognize viral transcripts and how viruses avoid being
detected by these degradation pathways will be of great help to further our understanding of the NMD
mechanism but also possibly contribute to finding new ways of interfering with virus replication and
hence prevent diseases.
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Abstract: The innate immune system has evolved a number of sensors that recognize viral RNA
(vRNA) to restrict infection, yet the full spectrum of host-encoded RNA binding proteins that target
these foreign RNAs is still unknown. The RNA decay machinery, which uses exonucleases to degrade
aberrant RNAs largely from the 5′ or 3′ end, is increasingly recognized as playing an important role
in antiviral defense. The 5′ degradation pathway can directly target viral messenger RNA (mRNA)
for degradation, as well as indirectly attenuate replication by limiting specific pools of endogenous
RNAs. The 3′ degradation machinery (RNA exosome) is emerging as a downstream effector of
a diverse array of vRNA sensors. This review discusses our current understanding of the roles of the
RNA decay machinery in controlling viral infection.
Keywords: RNA decay; RNA-protein interactions; decapping; Xrn1; exosome; TRAMP; exonuclease;
RNAse; intrinsic immunity; antiviral
1. Viral RNAs (vRNAs) as Foreign RNAs
RNA viruses produce RNAs which differ substantially from normal cellular RNAs, leading to
their recognition by host-encoded RNA-binding proteins. Unlike cellular RNAs, the genomes of RNA
viruses are replicated by RNA-dependent RNA polymerases (RdRp) through antigenome intermediates,
creating both transient double-stranded RNA (dsRNA) structures and 5′ triphosphate ends not normally
present in cellular messenger RNAs (mRNAs) [1]. For 5′ end protection and recruitment of the
translational machinery, endogenous mRNAs are capped in the nucleus. However, cytoplasmic RNA
viruses have no access to the normal cellular capping machinery and, thus, many of these viruses go to
great lengths to acquire a cap, including enzymatically synthesizing a cap or cap mimic, or acquiring
one from cellular mRNA through a process known as cap-snatching [2]. For translation and 3′ end
protection, most mRNAs are polyadenylated; some cytoplasmic viral mRNAs achieve this through
RdRp-mediated polyadenylation [3]. Furthermore, some viruses encode 3′ structures which impede
exonucleases [4,5]. These are but a few examples of the complexity of viral RNA (vRNA) metabolism,
which can render viruses susceptible to both immune sensors and the cellular RNA decay machinery.
2. Innate Immune Recognition of vRNA
2.1. RIG-I Like Receptors (RLRs) and DEAD-Box Helicases
The RNAs produced during viral replication serve as an important sign of infection, and a series
of sensors have evolved to detect these RNAs. In mammals, many cytosolic vRNAs are recognized
by the RIG-I-like receptors (RLRs), RIG-I and MDA-5, which are homologous DEAD-box RNA
helicases [6]. Each recognizes different RNA structures. RIG-I recognizes short dsRNAs and RNAs with
5′ triphosphates, and plays a role in restricting viruses, including paramyxoviruses, orthomyxoviruses,
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and flaviviruses [7,8]. In contrast, MDA-5 recognizes longer dsRNAs and higher-order RNA structures,
and is integral for recognition of picornaviruses [9,10]. Both can respond to the synthetic dsRNA
polyinosinic-polycytidylic acid (poly(I:C)) dependent on length; long poly(I:C) is a ligand of MDA-5,
while short poly(I:C) can activate RIG-I [11]. The RLRs primarily act by signaling the interferon
(IFN) system through their adaptor, MAVS; IFN then signals an extensive transcriptional antiviral
program [12–15]. A third RLR helicase, LGP2, lacks the ability to signal through MAVS, and in different
contexts has been found to either inhibit or potentiate the signaling of the other two RLRs [16–22].
In response, many RNA viruses have evolved mechanisms to evade the IFN system and, thus, avoid
the consequences of RLR detection; for example, both Rift Valley fever virus (RVFV) and Sindbis virus
(SINV) encode accessory proteins (NSs and nsP2) which inhibit the transcription of IFNs [23–27].
Just as mammalian cells utilize the RLR DEAD-box RNA helicases to recognize cytosolic vRNA,
the closest Drosophila homolog, Dicer-2, recognizes viral dsRNA intermediates generated during
infection [28–30]. However, Dicer-2 functions as both sensor and effector; in addition to its helicase
domain, it has a ribonuclease (RNase) III domain which cleaves dsRNAs into siRNAs which, in turn,
are loaded into the Argonaute 2-containing RNA-induced silencing complex, preventing RNA
translation and cleaving vRNA [31]. The antiviral RNA silencing pathway in Drosophila is essential for
immune defense; flies with mutations in this pathway rapidly succumb to viral infection. To evade
this immune defense, natural insect pathogens such as Drosophila C virus encode suppressors of
RNAi [29,32]. Dicer-2 also has silencing-independent antiviral functions which closely parallel the
signaling functions of the RLRs; Dicer-2 is required to induce the transcription of the antiviral factor
Vago, suggesting that it is also a regulator of antiviral transcription during viral infection in insects [33].
New roles are continually emerging for the larger family of DEAD-box helicases in recognizing
vRNA. Many of these genes have roles both in normal cellular metabolism as well as in the control
of viral infection. For example, DDX17 normally binds stem-loop structures of primary microRNAs
(pri-miRNAs) in the nucleus and recruits the Drosha-anchored microprocessor complex to produce
pre-miRNAs [34–37]. However, upon viral infection, DDX17 is repurposed and exported to the
cytoplasm, where it binds a stem-loop miRNA-like structure in RVFV RNA in order to restrict viral
replication [37]. Additional helicases are involved in innate recognition, such as the DEAD-box helicase
DDX60, which interacts with RIG-I, and the complex of DDX1, DDX21, and DHX36, which bind the
innate immune adaptor TRIF, in each case facilitating their activity [38,39].
2.2. Toll-Like Receptors (TLRs)
Endosomal RNAs are sensed by toll-like receptors (TLRs) including TLR3 and TLR7, which detect
dsRNA and ssRNA, respectively. These sensors signal through the adaptors TRIF and MyD88 to activate
antiviral transcription programs [6]. Endosomal TLRs are highly expressed in dedicated immune cells
such as dendritic cells, but are missing from many other cell types, which can only effectively sense
cytosolic RNA [40–42].
2.3. Protein Kinase R (PKR)
Mammalian cells possess additional cytosolic sensors of vRNA including the dsRNA-activated
protein kinase R (PKR) [43,44]. Activation of PKR by dsRNAs from viruses or poly(I:C) induces
autophosphorylation of PKR and subsequent phosphorylation of eIF2α, shutting down global protein
translation thereby preventing viral protein synthesis [45–48]. Many viruses prevent PKR-mediated
translational shutdown by binding dsRNA or PKR to prevent its activation [44,49]. Other viruses,
such as RVFV and poliovirus, induce PKR degradation [50–52]. In contrast, several other viruses, such as
hepatitis C virus (HCV) and SINV, encode RNA structures which bypass the PKR-dependent global
translational arrest and continue to be efficiently translated under these stress conditions [27,53–56].
Moreover, studies have found that RLR-dependent transcriptional activation is dependent on PKR
and vice-versa, suggesting crosstalk between these pathways [57,58].
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2.4. Ribonucleases (RNases)
Another cytoplasmic sensor of viral dsRNA, 2′-5′ oligoadenylate synthetase (OAS),
is an IFN-inducible enzyme and, thus, is up-regulated in response to viral detection by sensors, such as
the RLRs and TLRs [59,60]. Upon sensing vRNA, OAS synthesizes 2,5-adenylate, which, in turn,
activates the latent cytoplasmic endoribonuclease RNASEL. RNASEL cleaves vRNA and cellular RNA,
thereby inhibiting viral replication [61–63]. Furthermore, these cleaved RNAs can, in turn, act as
substrates for RLR detection, amplifying the antiviral program [64]. In addition, RNASEL promotes
apoptosis in response to viral infection, preventing further viral spread [65]. Recent studies have begun
to characterize RNAs as more or less susceptible to RNASEL and to postulate further functions for
RNASEL-mediated regulation of specific RNAs [66].
Drosha, a nuclear RNase III enzyme, has a canonical role in processing pri-miRNAs to pre-miRNAs
before they are exported to the cytoplasm for Dicer processing. Recent studies have shown that Drosha
has antiviral activity [67]. Drosha is exported to the cytoplasm in response to diverse RNA viruses, and
restricts RNA virus infection by unknown mechanisms, although it is likely that Drosha is recognizing
stem-loop structures in vRNA.
New research continues to uncover RNase activity among previously identified antiviral proteins.
SAMHD1 was identified as a restriction factor for human immunodeficiency virus (HIV) that is
antagonized by the viral protein Vpx [68]. An initial search for the antiviral mechanism revealed that
SAMHD1 is a deoxynucleotide triphosphohydrolase that degrades DNA nucleotides, restricting the
nucleotide pool available to HIV [69,70]. However, recent work has also identified 3′-5′ DNase and
RNase activity for SAMHD1, suggesting additional antiviral functions that may be active against HIV
and other viruses [71].
3. The Canonical RNA Decay Machinery and vRNA Targeting
Emerging data suggest that the canonical RNA decay machinery, which is largely dependent on
exonucleases, also plays an important role in antiviral immunity. In general, RNA decay proceeds from
either the 5′ or 3′ end of an RNA transcript, and has roles in RNA biogenesis, RNA quality control, and
normal RNA turnover. Ribosomal RNAs (rRNAs), small nuclear RNAs (snRNAs), and small nucleolar
RNAs (snoRNAs) all require RNA processing in the nucleus to reach their mature forms [72]. Quality
control also begins in the nucleus, where RNAs which fail to be properly matured, such as hypoadenylated
mRNAs and hypomodified tRNAs, are degraded before they can leave the nucleus [73,74]. In the
cytoplasm, additional quality-control checkpoints, such as nonsense-mediated decay or no-go decay,
detect stalled ribosomes or premature stop codons and degrade these aberrant mRNAs to release and
recycle the translational machinery [75]. Recent studies have shown that RNA decay machinery also
serves a key role in post-transcriptional regulation of groups of RNAs, called regulons, which are
rapidly co-regulated through specific recognition of sequences in their 5′ and 3′ untranslated regions
(UTRs) [76]. These include sequences such as terminal oligopyrimidines (TOPs) at the 5′ and AU-rich
elements (AREs) at the 3′ ends of RNAs [77–79]. As viruses possess many features of aberrant RNAs,
they are increasingly recognized as targets of the RNA decay machinery.
4. Antiviral Roles for Nonsense-Mediated Decay (NMD)
Nonsense-mediated decay (NMD) is the process by which mRNAs with stop codons far from the 3′
end of an mRNA, either due to a premature stop codon or a long 3′ UTR, are detected and degraded at
either the 5′ or 3′ ends [75,80,81]. Several RNA viruses have been shown to be sensitive to this pathway.
In particular, the NMD components Upf1, Smg5, and Smg7 restrict the replication of Semliki Forest
virus (SFV) in mammalian cells [82]. The mechanism of this restriction is unclear, and may act through
degradation of vRNA or indirect effects; it is independent of viral 3′ UTR length, suggesting that the
long 3′ UTR of SFV mRNA is not necessary for NMD sensitivity. The antiviral effect of NMD is ancient;
several plant NMD orthologs, including Upf1, were found to restrict potato virus X by recognizing
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vRNAs with long 3′ UTRs [83]. NMD is also antagonized by viruses; both HCV and human T-cell
leukemia virus type 1 produce proteins which inhibit NMD, suggesting evolutionary pressure to evade
this antiviral mechanism [84,85].
5. 5′ Decapping and Decay
Endogenous mRNAs targeted for 5′ decay are typically first deadenylated by the CCR4-NOT
complex, often assisted by other deadenylating enzymes, before they can be targeted for decay [80,86].
Although deadenylation is the first regulated step towards mRNA degradation, it is sometimes
reversible, and can act to “pause” mRNA translation rather than degrading these targets [87]. Removal
of the 5′ cap of RNA by decappers (e.g., Dcp2) is irreversible, and permits degradation by the 5′–3′
exonucleases Xrn1 and Xrn2, in the cytoplasm and nucleus, respectively [88–90]. This process is largely
conserved from yeast to mammals, though mammals have evolved multiple, partially-redundant
decapping enzymes with specificity for different targets; Dcp2 is preferentially utilized in NMD and
Nudt16 is preferentially involved in degradation of mRNAs containing AREs or 5′ TOPs [77,91].
Deadenylation, decapping, and 5′ degradation activities coalesce in ribonucleoprotein (RNP)
structures known as processing bodies (P bodies). These RNPs consist of mRNAs targeted for decay as
well as components of the decapping and 5′ degradation machinery (including Dcp2, its activators,
and Xrn1) [86,92]. RNAs that accumulate in P bodies are removed from translation, and normally
degraded [93]. Although P-bodies are present in normal cells at baseline, their number and size
increase in response to a variety of stressors [94,95]. P bodies can interact with and exchange RNAs
with other RNP granules, such as stress granules, which are composed of translationally-stalled RNAs
and chaperone proteins [95,96]. There is evidence that visible P bodies are a consequence of high
concentrations of mRNAs undergoing decay rather than being necessary for decay, as P body structure
can be disrupted without preventing RNA degradation [97,98]. Furthermore, up-regulation of 5′
decapping and decay leads to the loss of visible P bodies due to the depletion of RNA targets [77].
These data suggest that P bodies are dynamic structures which form and dissolve in response to RNA
target levels.
6. Antiviral Roles for 5′ to 3′ RNA Decay
The 5′ to 3′ RNA decay machinery can inhibit viral replication in a number of different ways
(Figure 1). Studies have shown that the cytoplasmic 5′ RNA exonuclease, Xrn1, can target flavivirus
RNAs and in response these viruses antagonize Xrn1 by encoding structured RNAs that result in Xrn1
stalling [99–101]. Furthermore, poliovirus induces the degradation of host 5′ decay factors, such as
Xrn1 and Dcp2, through a combination of viral and host proteases, suggesting evolutionary pressure
to evade host 5′ RNA decay machinery [102]. In addition to directly targeting vRNAs, the 5′ decay
machinery can also impact viral replication indirectly. Recent studies have shown that decappers
limit the pool of host mRNAs available for RVFV to cap snatch from, attenuating replication in both
insects and mammals [77,103]. Additionally, in mammals, RVFV infection induces NUDT16-mediated
decapping and decay of 5′ TOP-containing mRNAs encoding the translational machinery, limiting
both global and virus-specific translation [77].
P body structure is also altered during many viral infections. The up-regulation of 5′ decay
during RVFV infection prevents the formation of P bodies due to depletion of the RNA targets around
which they nucleate [77]. Poliovirus induces the degradation of 5′ decay proteins such as Xrn1 and
Dcp1a, preventing P body formation [102]. In addition to the destruction of P bodies during some
viral infections, P body components can be repurposed by viruses to facilitate infection. Flaviviruses
relocalize P body components to viral replication centers, where they bind viral 3′ UTRs, promoting
efficient viral replication [104–106].
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Figure 1. The 5′ to 3′ decay machinery can inhibit viral infection directly through degradation of viral
RNA (vRNA; flaviviruses) or indirectly through decapping and degradation of RNAs needed for viral
transcription and translation (bunyaviruses). The 3′ to 5′ decay machinery, the RNA exosome, interacts
with a variety of RNA-binding proteins, some of which are exported to the cytoplasm in response to
viral infection. Recruitment of the exosome can result in degradation of vRNA.
7. The RNA Exosome
3′ to 5′ degradation is largely mediated by the RNA exosome. This complex consists of a hexameric
barrel (six proteins with RNase PH homology) and a cap structure (three proteins with S1 RNA-binding
domains) [107–109]. These structural components of the exosome form an internal channel wide
enough to permit entry of single-stranded but not double-stranded RNA [110]. In contrast to the
5′ decay machinery which localizes to cytoplasmic P bodies, exosome components are both nuclear and
cytoplasmic, and can accumulate in poorly-understood RNP granules [92,111–113]. While exosome
proteins share structural and sequence homology to RNases, the structural components of the exosome
are not believed to contribute directly to RNA degradation in vivo. Rather, in yeast, where it has been
extensively characterized, 3′ to 5′ exonuclease activity is performed by two exosome-associated RNA
exonucleases: Rrp6, which is exclusive to the nucleus, and Dis3, which is present in both the nucleus
and the cytoplasm [114–116].
The exosome is both structurally and functionally conserved from yeast to humans [117].
Indeed, mutations in the yeast exosomal genes Rrp4, Csl4, or Dis3 can be complemented with the
human orthologs [116]. Interestingly, the localization of the exosome exonucleases has diverged over
evolutionary history. Rrp6 is present in both the nuclear and cytoplasmic fractions of human cells,
and Dis3 has two additional paralogs in humans, Dis3L1 and Dis3L2, which function exclusively in the
cytoplasm [118]. Dis3L2, which lacks the exosome-associating PIN domain, operates independently
of the larger exosome complex in a separate 3′ to 5′ degradation system which favors terminally
uridylated RNAs [119–121].
Though the exosome degrades RNAs indiscriminately in vitro, it degrades RNAs in vivo in
a regulated fashion by relying on RNA-binding cofactor complexes that bind specific targets and
recruit the exosome for degradation [122]. All known exosome cofactor complexes are anchored by
helicases which are thought to unwind higher-order RNA structures to permit single-stranded RNA
to be inserted into the exosome barrel for decay [123]. Different RNAs are targeted by the exosome
in the nucleus, nucleolus, and cytoplasm; therefore, the exosome relies on different cofactors in each
subcellular compartment to target these diverse RNAs for decay. Two major complexes, the cytoplasmic
Ski and nuclear TRAMP complexes, have been extensively characterized in yeast.
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The Superkiller (Ski) complex is the major cytoplasmic exosome cofactor complex in yeast, named
for the “superkilling” phenotype of dsRNA viruses, which are lethal to yeast deficient in these
genes [124]. The Ski genes were identified before the discovery of the exosome, and some components of
the exosome barrel were also assigned Ski names. Though mutants in cofactor Ski genes lead to increased
vRNA, this has not yet been definitively linked to exosomal RNA degradation [125]. The Ski complex
consists of a DExH/D-box helicase, Ski2, a tetratricopeptide repeat-containing protein, Ski3, and a WD
repeat-containing protein, Ski8 [126]. An adaptor G-protein, Ski7, physically links the Ski complex and
the exosome and is required for Ski complex-mediated decay [127]. The Ski complex is involved in
recruiting the exosome to RNAs targeted for NMD, as well as nonstop decay [128–130]. Orthologs for
all three Ski genes are present in higher organisms, though their specific targets have not been clearly
defined [131,132]. Interestingly, a recent paper found that the human Ski complex-associated helicase
SKI2L prevents hyper-activation of RIG-I in uninfected cells, protecting cells from autoimmune
activation and patients harboring mutations in this gene presented with anomalously high IFN
signatures [133]. Though the exosome was not shown to be required for this activity, it does suggest
that the Ski-associated helicase, potentially with the exosome, may serve to protect the intracellular
milieu from overactive RIG-I signaling, paralleling the role of the DNA exonuclease TREX, which
degrades cytoplasmic DNA to prevent hyper-activation of the DNA sensor cGAS [134–136].
The yeast TRAMP (Trf4/5-Air1/2-Mtr4-Polyadenylation) complex, located in the nucleus,
has known roles in degrading hypomodified tRNAs, hypoadenylated mRNAs, cryptic unstable
transcripts (CUTs), and in the biogenesis of rRNA, snRNA, and snoRNA [72–74,122,137,138].
The complex is anchored by a DExD/H box helicase, Mtr4, which binds the other TRAMP components
through its arch domain [123,139]. The Zn-knuckle RNA-binding proteins Air1 and Air2 bind
specific RNAs and target them for degradation [140]. These two proteins are partially functionally
redundant; mutants in each protein accumulate overlapping but non-identical populations of snRNAs,
snoRNAs, and mRNAs, and double-mutant strains fail to grow. Trf4 and Trf5 are non-canonical poly(A)
polymerases which add 5–6 adenines to RNAs bound to the TRAMP complex [137]. The addition of
short poly(A) tails creates an unstructured 3′ end which is thought to facilitate insertion of the RNA
into the exosome barrel [141]. This adenylation parallels the role of polyadenylation in Escherichia coli,
which, unlike eukaryotic polyadenylation, targets RNAs for decay [142,143]. In addition to the
canonical TRAMP complex, Mtr4 can form other modular cofactor complexes by associating with the
adaptors Nop53 or Utp18, which assist in some rRNA maturation steps [144].
The TRAMP complex is conserved in humans, but nuclear RNA degradation machinery has
additional complexity. As in yeast, human TRAMP is composed of a helicase, hMTR4, a zinc-finger
Air-like protein, hZCCHC7, and a poly(A) polymerase, hTRF4-1 or hTRF4-2 [145,146]. However, unlike
yeast TRAMP, the human TRAMP complex is restricted to the nucleolus, and is only known to process
rRNA [145,147]. Most of the yeast TRAMP targets, such as mRNAs, snRNAs, snoRNAs, and promoter
upstream transcripts (PROMPTs, which are analogous to yeast CUTs) appear to be regulated in human
cells by the nuclear exosome targeting (NEXT) complex, which shares hMTR4 with the TRAMP complex,
but also contains the zinc-finger protein hZCCHC8 and the RNA-binding motif protein hRBM7 [145,
148,149]. Other targets are likely to exist for mammalian TRAMP-like complexes; murine cells depleted
of Mtr4 accumulate adenylated 5′ miRNA fragments, suggesting that adenylation and Mtr4-mediated
degradation may be important for these RNAs [150]. The full spectrum of Mtr4-anchored complexes
in mammals and the regulation of other classical yeast TRAMP targets (such as misprocessed tRNAs)
remain unclear.
8. Antiviral Roles for the RNA Exosome and 3′ Decay
Studies have implicated the exosome in antiviral defense. A number of antiviral RNA-binding
proteins co-immunoprecipitate with the exosome, suggesting that their mechanism of action may
involve exosomal degradation. DDX17 restricts RVFV by binding a miRNA-like stem loop structure
encoded in the vRNA [37]. Though its mechanism of restriction is unknown, DDX17 binds to the
29
Viruses 2017, 9, 2
exosome, suggesting that it directly recruits the exosome to degrade these bound vRNAs [145,151].
DDX60, which is antiviral against vesicular stomatitis virus (VSV), also binds the exosome [39].
However, DDX60 does not depend on the exosome for its antiviral function, but rather bridges
vRNA and RLRs to potentiate signaling. The cytidine deaminase AID, which binds the exosome
and hepatitis B virus (HBV) RNA in a complex, is antiviral when overexpressed only if the exosome
is present, suggesting the possibility that it recruits the exosome to degrade HBV RNA [152]. The
zinc-finger antiviral protein (ZAP) binds SINV and retrovirus RNA, as well as components of the
exosome [153]. In overexpression systems, ZAP restricts MLV viral replication in an exosome-dependent
fashion, as well as affecting the expression and stability of viral luciferase reporters for both MLV and
HIV [154,155]. It remains unclear if the exosome is required for the activity of endogenous ZAP or
degrades ZAP-bound vRNAs. The cell biology of these factors is largely unexplored, but overexpressed
DDX60 and ZAP localize to the cytoplasm, while overexpressed AID binds the exosome in both the
nucleus and cytoplasm [39,152,156]. In response to viral infection, DDX17 translocates from the nucleus
to the cytoplasm where the vRNAs are located [37].
Recent work has implicated the exosome and components of a canonical cofactor complex in
the direct recognition and degradation of specific vRNAs. RNAi screening revealed an antiviral role
for exosome core components as well as the TRAMP components Mtr4 and Zcchc7 against three
RNA viruses from distinct families, VSV, SINV, and RVFV, in both Drosophila and human cells [157].
Though TRAMP components are normally nucleolar, infection with these cytoplasmic viruses leads
to the export of hMTR4 and hZCCHC7 to the cytoplasm, where they complex with the exosome and
specifically bind viral mRNAs. Further study found that RVFV mRNA is destabilized by the exosome
and hZCCHC7, and that the 3′ UTR of RVFV mRNA is sufficient to render a reporter RNA susceptible
to exosomal degradation during viral infection. Cell biological studies showed that hZCCHC7 localizes
to cytoplasmic punctae during viral infection, suggesting that it may be recruited to RNP granules for
its antiviral function.
Taken together, these studies suggest that the exosome is a broad antiviral effector downstream
of diverse sensors which bind distinct vRNAs to recruit the exosome for degradation (Figure 1).
Though the exosome has been shown to degrade vRNA sensed by some of the proposed exosomal
cofactors, such as Mtr4. Zcchc7, and ZAP, much work remains to describe the mechanism and exosomal
involvement in antiviral restriction downstream of the other proteins.
9. Concluding Remarks
Increasing evidence suggests that the RNA decay machinery plays important roles in antiviral
defense. This can involve either direct effects on vRNA stability or indirect regulation of the intracellular
milieu. Furthermore, an emerging theme suggests that many RNA binding proteins can be repurposed
from their endogenous roles in the nucleus to antiviral roles in the cytoplasm. Future studies are
necessary to further elucidate how these RNA binding proteins recognize foreign RNAs and how they
interface with the RNA decay machinery to restrict vRNA replication.
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Abstract: Positive-strand RNA viruses have evolved multiple strategies to not only circumvent the
hostile decay machinery but to trick it into being a priceless collaborator supporting viral RNA
translation and replication. In this review, we describe the versatile interaction of positive-strand
RNA viruses and the 5′-3′ mRNA decay machinery with a focus on the viral subversion of decapping
activators. This highly conserved viral trickery is exemplified with the plant Brome mosaic virus,
the animal Flock house virus and the human hepatitis C virus.
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1. Introduction
Viruses maintain a constant duel with their infected host cells. Not only do they evolve strategies
to circumvent deleterious cellular responses, but they also take advantage of the rich pools of host
factors as controllable resources. Hijacking these resources is essential for the expansion of viruses
as their gene-coding capacity is limited. One exquisite example of such viral manipulation is the
use of the cellular mRNA decay machinery by a group of positive-strand RNA ((+)RNA) viruses.
They use different strategies to turn the mRNA decay proteins into allies that support their replication
and expansion.
The (+)RNA virus group includes numerous plant, animal and human pathogens such as the
hepatitis C virus (HCV) and the emerging mosquito-borne Zika virus (ZIKV), Dengue virus (DENV),
West Nile virus (WNV) and Chikungunya virus (CHIKV). Despite their diversity in terms of genome
organization or virion morphology, the replication cycle of (+)RNA viruses is highly conserved [1].
Upon entering the target cell and gaining access to the cytoplasm, their single-stranded RNA genomes
act like mRNAs and are directly translated by the host translation machinery to express the viral
proteins. Once viral proteins accumulate, translation is repressed and the viral genomes are specifically
recruited from the cellular translation machinery into membrane-bound viral replication complexes,
where they act as templates for replication. Thus, to ensure productive infection, (+)RNA genomes
must express enough viral protein to initiate the replication process and must keep their 5′ and 3′ ends
intact to synthesize functional copies of the viral RNA. Hence, it is no surprise that for (+)RNA viruses
to expand, the host mRNA decay machinery must be tricked (reviewed in [2]).
Cytoplasmic mRNA decay occurs via two major pathways—the deadenylation-dependent
5′-3′ decay and the exonucleolytic 3′-5′ decay pathways—that are conserved in all eukaryotes
(Figure 1) [3]. In both pathways, the 3′ poly(A) tail protects the mRNAs from degradation. Consequently,
mRNAs are targeted to degradation only after the deadenylation complex Ccr4/Pop2/Not or
Pan2/Pan3 [4,5] shortens the 3′ poly(A)-tail. This leads to the opening of the closed-loop messenger
ribonucleoprotein particle (mRNP) formed between the poly(A)-binding protein (PABP) and the
cap-complex. Deadenylation is modulated by translation per se, by RNA binding proteins or by
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stress. Once deadenylation has occurred, mRNAs undergo degradation in the 5′-3′ direction, via
decapping and subsequent degradation, or/and in the 3′-5′ direction, via the exosome complex. Besides
these two major mRNA decay pathways, there are several specialized ones that primarily function in
response to aberrancies in translation and are hence called mRNA quality control pathways (reviewed
in [6]). These pathways are based on either deadenylation-independent decay [7], rapid 3′ to 5′
decay [8] or endonuclease cleavage [9] and include the nonsense-mediated decay (NMD), the no-go
decay (NGD) and the non-stop decay (NSD) pathway.
Figure 1. The two main mRNA decay pathways in the cytoplasm: The deadenylation-dependent 5′-3′
decay pathway and the exonucleolytic 3′-5′ decay pathway. Pan2/Pan3: PAB-dependent poly(A)-specific
ribonuclease subunits; Pop: PGK promoter directed OverProduction; Not: Negative regulator of
transcription subunit; Ccr4: C-C motif chemokine receptor 4; Dcp1/Dcp2: mRNA-decapping enzyme
subunit 1/2; Xrn1: 5′-3′ exoribonuclease 1.
The deadenylation-dependent 5′-3′ decay pathway is the main cytoplasmic decay pathway
(reviewed in [3]). mRNA-decapping enzyme subunit 2 (Dcp2) and 5'-3' exoribonuclease 1 (Xrn1) are
the two key enzymes in this pathway. Dcp2 cleaves the cap structure at the 5′ end of the mRNA,
releasing a 7-methylguanosine diphosphate (m7GDP) and a 5′ monophosphate mRNA. To be fully
active, Dcp2 requires a conformational change mediated by the Dcp1 protein. The other enzyme is the
5′-3′ exonuclease Xrn1 that degrades the mRNA after decapping. In addition, there are other factors,
named decapping activators, that assist and enhance the efficacy of the pathway. They include Sm-like
proteins 1–7 (Lsm1–7), DNA topoisomerase 2-associated protein (Pat1), DExD/H-box ATP-dependent
RNA helicase 1 (Dhh1), enhancer of mRNA-decapping protein 1–3 (Edc1–3) and the Suppressor of
Clathrin Deficiency (Scd6). From these, Lsm1–7, Pat1 and Dhh1 are the most characterized ones.
The Lsm1–7 ring is constituted by seven Lsm proteins that belong to the conserved Sm family
of proteins and acts as an RNA chaperone facilitating a variety of RNA-RNA and RNA-protein
interactions [10]. Pat1 functions as a scaffold protein, allowing the sequential binding of decay factors
on mRNPs that eventually leads to degradation [11]. Lsm1–7 and Pat1 are co-purified from yeast
extracts as a complex [12]. Finally, Dhh1 belongs to the family of DEAD box helicases characterized by
acting as RNA chaperones as well. In the 5′-3′ deadenylation-dependent decay pathway, degradation
occurs in three-steps. First, translation initiation is inhibited, as mRNA translation initiation and mRNA
decay are connected processes in dynamic competition. This is achieved by the concerted action of the
deadenylation complex and the decapping activators Dhh1, Lsm1–7, Pat1 and Scd6. Deadenylation
leaves the 5′ cap structure accessible for the decapping complex Dcp1/Dcp2 while Dhh1, Pat1 and
Scd6 inhibit translation initiation [13–15]. Dhh1 also hinders translation elongation by slowing down
the ribosomes [16]. Although repression of translation initiation is required for decapping, it does not
inevitably lead the mRNA to decapping as some mRNAs remain in a translationally-repressed state.
Such translationally-repressed mRNAs can be stored in processing bodies (P-bodies), non-membranous
40
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dynamic cytoplasmic foci, and go back to translation or be further processed for degradation [17,18].
Second, the 5′ cap is removed by the Dcp1/Dcp2 decapping complex. The activity of the complex is
accelerated by the decapping activators Lsm1–7, Edc1–3 and Pat1 [14,19–21]. Third, the exonuclease
Xrn1 now has access to the uncapped mRNA and degrades it in the 5′-3′ direction.
The (+)RNA viruses have developed a myriad of strategies to shield their RNA from degradation
by Xrn1, often by directly suppressing or degrading the cellular decay machinery. For example,
picornaviruses use an aggressive mechanism to combat decay by inducing the rapid degradation of
Xrn1 and Dcp1 [22,23]. WNV and DENV use Xrn1 to specifically generate sub-genomic flavivirus RNA
(sfRNA) from the genomic RNA (gRNA) [24]. Degradation of gRNA by Xrn1 is stopped by a highly
conserved RNA structure at the beginning of the 3′ untranslated region (UTR). The generated sfRNA
plays essential roles in viral replication and pathogenesis in human hosts [24] and in mosquitoes as it
inhibits the RNA interference (RNAi) response [25] and determines the infection and transmission
rates [26]. Interestingly, the generated sfRNA displays an additional role. It binds to and inhibits Xrn1,
hence, the endogenous mRNA turnover is altered [27–29]. This deregulated host mRNA stability is
directly related to sfRNA expression and plays an important role in pathogenesis. As found for WNV
and DENV, both the HCV and the Bovine viral diarrhea virus (BVDV) contain regions that stall and
repress the enzymatic activity of Xrn1 [30]. However, in these two viruses, the regions are located
in the 5′ UTRs. Intriguingly, other (+)RNA viruses, rather than avoiding or using the degradation
activity of the 5′-3′ deadenylation-dependent decay machinery, redirect it to other functions. This
review describes the strategies of the Brome mosaic virus (BMV), the Flock house virus (FHV) and
HCV as representative plant, animal and human (+)RNA viruses that subvert the cellular decapping
machinery to promote translation and replication of their viral RNA genomes.
2. The Brome Mosaic Virus Converts Enemies into Collaborators in Order to Promote Viral RNA
Translation and Replication
A fruitful model system to study (+)RNA virus–host interactions is the replication of the plant
BMV in Saccharomyces cerevisiae (reviewed in [31,32]). The BMV genome consists of three RNAs that
are capped at their 5′ end, and at their 3′ end carry a conserved tRNA-like structure (TLS) instead of a
poly(A) tail. Both UTRs contain overlapping sequences that control translation and the initiation of
negative-strand synthesis (reviewed in [33]). RNA1 and RNA2 encode helicase 1a and polymerase
2a, respectively. The helicase 1a protein is the only viral protein required to recruit the BMV genome
from the cellular translation machinery to the viral replication complex. RNA3 encodes the movement
protein 3a and through a sub-genomic RNA generated during replication, the coat protein. Both
proteins are required for the systemic infection of plants but not for viral replication.
Studies with the BMV/yeast model system led to the identification and characterization of
hundreds of host factors required for different steps in the BMV life cycle [34,35]. Three unexpected
factors were the decapping activators Lsm1–7, Pat1 and Dhh1. Depletion of the Lsm1–7, Pat1 or
Dhh1 proteins dramatically reduced both BMV RNA translation and recruitment from translation
to replication of the BMV RNA genomes [36–41]. Other components of the decay machinery are
not required for these functions, indicating that BMV specifically subverts a selected group of decay
factors [39]. The role of the Lsm1–7/Pat1 complex and the RNA helicase Dhh1 in translation has been
thoroughly characterized. Both the Lsm1–7/Pat1 complex integrity and its intrinsic RNA-binding
activity are required for translation of BMV RNAs [35]. The Lsm1–7/Pat1 complex directly interacts
with sequences in both BMV RNA UTRs and with two internal A-rich single-stranded regions located
in one of the BMV RNAs [34,35]. These sequences include well-characterized RNA motifs that control
BMV RNA translation and replication. In turn, the helicase Dhh1 directly interacts with BMV RNA
3′ UTRs but not with the 5′ UTR. However, Dhh1 interacts with the translation initiation factors
eIF4E, eIF4A and eIF4G located at the 5′ UTRs [42]. In addition, Dhh1 was found to bind sequences
within the open reading frame (ORF) of BMV RNA2 (Figure 2). Importantly, Lsm1–7/Pat1 and Dhh1
targeted sequences are linked to the dependence on Lsm1–7/Pat1 and Dhh1 for translation, suggesting
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that their intrinsic RNA binding characteristics determine their function [37,39,42]. Recent exciting
results indicate that Dhh1 also promotes translation of a specific set of cellular mRNAs encoding
membrane and secreted proteins [42]. Viral and cellular Dhh1-dependent mRNA share some common
key features. First, they contain long and highly structured 5′ UTRs and ORFs, including a region
located close to the starting AUG. Second, they are directly bound by Dhh1 with a specific binding
distribution. Third, they are likely activated by Dhh1 at the translation initiation step. Last, they
encode proteins that localize in membranes. Whether Lsm1–7/Pat1 may exert a similar function on
cellular mRNAs remains unknown.
Figure 2. Binding pattern for DExD/H-box ATP-dependent RNA helicase 1 (Dhh1) and the
Lsm1–7/Pat1 complex to brome mosaic virus (BMV) RNA2. Dhh1 binds to three sites in the open
reading frame (ORF) and to the tRNA-like structure (TLS) in the 3′ untranslated region (UTR) (purple
color). The Lsm1–7/Pat1 complex binds to both the TLS and the non-tRNA-like structure in the 3′ UTR
and also with lower affinity to the 5′ UTR (green color).
The mechanisms by which the Lsm1–7/Pat1 complex promotes translation and recruitment
of BMV RNAs are different. Mutations in the LSM1 gene, a key component of the Lsm1–7 ring,
affect differentially BMV RNA translation and recruitment [35]. Importantly, the Lsm1–7 Pat1 complex
interacts in a RNAse-resistent manner with the BMV 1a, the solely viral protein required for recruiment.
In line with this, the RNA-biding activity of the Lsm1–7/Pat1 complex is not requried for its function in
recruitment [38]. The molecular mechanisms by which Dhh1 promotes BMV RNA recruitment remain
uncharacterized. Taken together, the decapping activators Lsm1–7, Pat1 and Dhh1 bind specifically
to the BMV RNA genome, promoting its translation and replication rather than its decay. Current
results support a model (Figure 3) in which Lsm1–7, Pat1 and Dhh1 bind to cis-elements in the
viral RNA, thereby remodeling mRNA secondary structures and promoting its circularization and
translation. Since poly(A)-tails in cellular mRNAs mediate 5′-3′ circularization via the binding of the
poly(A) binding protein, binding of Lsm1–7, Pat1 and Dhh1 to the 5′ and 3′ UTRs structure and to
initiation factors at the 5′ UTR would establish such circularization in BMV RNAs. During recruitment,
circularization would be disrupted as the Lsm1–7/Pat1 complex would now bind to the viral 1a
protein, driving the viral RNA from translation to replication.
Figure 3. Model of the Lsm1–7/Pat1 complex and Dhh1 function in viral RNA translation and recruitment.
3. The Flock House Virus Subverts Features of Decapping Proteins to Control the Genomic to
Sub-Genomic Viral RNA Ratio
The FHV (reviewed in [43]) is an insect pathogen that can replicate in a wide variety of hosts,
including Drosophila, Caenorhabditis elegans, plants, mammals and Saccharomyces cerevisiae. Accordingly,
the host factors hijacked by FHV to replicate are highly conserved [44–47]. The simplicity of the FHV
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genome, combined with the advantages of yeast genetics make the FHV-yeast system another excellent
model system to study basic aspects of (+)RNA biology, including virus–host interactions. Interestingly,
three of the highly conserved host factors subverted by FHV are the decapping activators Lsm1–7, Pat1
and Dhh1 [48].
The FHV bipartite genome consists of two capped but non-polyadenylated RNA segments. RNA1
encodes protein A, the only FHV protein required for replication, and RNA2 encodes the capsid
precursor. During replication, RNA1 also produces sub-genomic RNA3 that encodes protein B1,
of unknown function, and protein B2, required to suppress RNA silencing in infected hosts. RNA3
corresponds to the 3′ end of RNA1 and it is synthesized during RNA1 replication. In addition to its
coding function, RNA3 coordinates the production of appropriate levels of RNA1 and RNA2 [49–51].
This latter activity is essential for proper and timely expression of the different viral proteins throughout
the different stages of the viral life cycle. Interestingly, depletion of Lsm1–7, Pat1 or Dhh1 disrupts this
activity and alters the RNA1/RNA3 ratio [48].
Lsm1–7, Pat1 and Dhh1 control RNA3 synthesis [48]. Different RNP rearrangements of the genomic
RNA1 are necessary for the viral polymerase to synthesize a complete copy of RNA1 or a partial one,
RNA3 [50]. RNA3 synthesis requires a long-distance base pairing interaction between cis-elements in
RNA1 [50]. These base pairing interactions stop the polymerase prematurely and lead to the synthesis
of RNA3 instead of RNA1. As Dhh1 remodels RNP compositions in an ATPase-dependent manner [52]
and RNA3 synthesis requires the ATPase activity of the Dhh1 helicase [48], Lsm1–7, Pat1 and Dhh1
have been proposed to regulate the key viral RNP transitions required to maintain the balance between
the alternative FHV RNA1 conformations controlling RNA3 synthesis [48]. Interestingly, and as found
for BMV, Lsm1–7, Pat1 and Dhh1 interact not only with the RNA genome but also with the viral
polymerase [48].
4. Subverting Decapping Activators Is Conserved in Human (+)RNA Viruses
Since the 5′-3′ decay pathway is strongly conserved from yeast to humans, human (+)RNA
viruses might as well subvert it to favor viral replication. Indeed, the human counterparts of Lsm1–7,
Pat1 and Dhh1—namely Lsm1–7, PatL1 and DEAD-Box Helicase 6 (DDX6)—are required for the
expansion of the flaviviruses HCV, DENV and WNV. Depletion of Lsm1–7, PatL1 or DDX6 directly and
specifically inhibits HCV RNA translation and replication [53,54]. Moreover, in vitro binding assays
demonstrated direct interactions of human Lsm1–7 complexes with essential translation/replication
regulatory sequences in the 5′ and 3′ UTRs of the HCV RNA genome [53]. DDX6 also interacts with
the HCV RNA genome and the core protein in HCV-infected cells [55]. Likewise, DDX6 and Lsm1
promote replication of the WNV and co-localize with the viral replication complex [56]. Moreover,
DDX6 directly interacts with structured regulatory cis-sequences in the DENV RNA genome and it
co-localizes with the DENV replication complex [57].
Although all the above described examples of (+)RNA viruses belong to the Flaviviridae family, the
conserved use of decapping factors by (+)strand RNA viruses that infect plants (BMV), insects (FHV)
and even bacteria (Qβ [58]) underlines the robustness of this strategy to regulate (+)RNA virus life
cycles and suggests that it extends to other human viruses outside the Flaviviridae family. Depriving
(+)RNA viruses of this highly conserved strategy by targeting these decay factors with drugs would
therefore appear to be a promising strategy to generate broad-spectrum antiviral drugs. The fact that
the individual, transient knock-down of Lsm1–7, PatL1 or DDX6 proteins in human cells is not toxic
and that the respective yeast knockout strains are viable, stresses the feasibility of such an approach
for the future.
What are the common features of the aforementioned activities of Lsm1–7, Pat1/PatL1 and
Dhh1/DDX6 in (+)RNA viral life cycles? In all cases, the decapping activators interact with viral
replication proteins, and/or with specific and structured regulatory cis-acting signals in the viral
RNA genome. The role of these decapping proteins as catalyzers of mRNP transitions that direct
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cellular mRNAs from translation to decay suggests that they act similarly on the highly structured
viral (+)RNA genomes, directing them to translation or replication.
5. (+)RNA Viruses Alter the Distribution of Decay Factors
Lsm1–7, PatL1 and DDX6 accumulate in P-bodies [59,60]. P-bodies are discrete and highly
dynamic cytoplasmic mRNP granules found in eukaryotic cells under normal growth condition [59].
These structures contain translationally-repressed mRNAs together with multiple proteins from the
5′-3′ mRNA decay and silencing machineries [60]. Once in P-bodies, mRNAs can be either degraded
or stored for future translation [17,61,62]. The components of P-bodies cycle rapidly in and out
of these granules, indicating that there is a constant exchange with the cytoplasm where all these
components are diffusely distributed [63–65]. Importantly, the formation of P-bodies requires most
of its components [11,63,66–69]. Consequently, conditions that reduce the cytosolic concentration
of P-body proteins, such as (+)RNA virus infection, disrupt the formation of P-bodies (Figure 4).
For example, the picornaviruses poliovirus and Coxsackie virus disrupt P-bodies by degrading the
P-body core components Xrn1 and Dcp1a [22,23], and HCV, WNV and DENV do so by preventing
Lsm1–7, PatL1 and DDX6 from participating in P-body formation [70–72]. All these results were
obtained in cell culture infection systems. Importantly, HCV inhibits P-body granule formation in
human livers regardless of viral phenotype, inflammation grade or whether infection was recent or
long established. Moreover, this alteration is reversed once HCV is eliminated by therapy. Therefore,
there is a link between P-body alterations and pathogenic conditions [73].
Figure 4. (+)RNA viruses and the cellular mRNA decay machinery. Multiple strategies have been
developed by (+)RNA viruses to not only prevent the degradation of the viral RNA genomes but also,
to subvert it to their benefit. P-bodies: processing bodies; WNV: West Nile virus; DENV: Dengue
virus; HCV: hepatitis C virus; BVDV: bovine viral diarrhea virus; FHV: Flock house virus; BMV: brome
mosaic virus.
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The obvious question to ask is whether P-body disruption is required for viral infection or whether
it is just a consequence. The data currently available suggest that it is a mere consequence, as P-body
formation is not required for mRNA decay [74] and depletion of the P-body component Rap55 disrupts
P-body formation but it does not affect HCV expansion [70]. Irrespective of the question whether
P-body disruption is the consequence or the trigger of pathogenesis, it seems obvious that changing
the equilibrium of granulated versus free P-body proteins, proteins that control decay and silencing,
would alter the transcriptome and translatome and consequently gene expression. These alterations
might be linked to different viral pathologies. Accordingly, to further study the interactions of (+)RNA
viruses with P-bodies represents an interesting field that may open many opportunities in terms of
therapeutic strategies.
6. Concluding Remarks
Viruses are masters in converting hostile conditions into a paradise for their own replication. The
sequestering of the cellular decay machinery by (+)RNA viruses is a remarkable example of this that goes
beyond using the decay components themselves towards altering the whole transcriptional/translational
landscape of the host. The strong conservation of this viral strategy across species pinpoints a weak
spot that can be exploited for the development of broad-spectrum antiviral drugs. Yet, some essential
questions remain open. For example, how are viral infection, the host transcriptome/translatome and
pathogenesis linked? How do viruses regulate host transcription to favor their own replication? The
basic nature of these questions highlights that scientists in this area still have a long path to go.
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Abstract: To successfully replicate, viruses protect their genomic material from degradation by the
host cell. RNA viruses must contend with numerous destabilizing host cell processes including
mRNA decay pathways and viral RNA (vRNA) degradation resulting from the antiviral response.
Members of the Picornaviridae family of small RNA viruses have evolved numerous diverse strategies
to evade RNA decay, including incorporation of stabilizing elements into vRNA and re-purposing
host stability factors. Viral proteins are deployed to disrupt and inhibit components of the decay
machinery and to redirect decay machinery to the advantage of the virus. This review summarizes
documented interactions of picornaviruses with cellular RNA decay pathways and processes.
Keywords: picornavirus; Picornaviridae; poliovirus; coxsackievirus; human rhinovirus; RNA
degradation; mRNA decay; RNA stability; RNase L; deadenylase
1. Introduction
Cytoplasmic RNA viruses encounter a myriad of host defense mechanisms that must be countered
by a small arsenal of viral proteins. Preserving the stability and integrity of viral RNA (vRNA) is of
fundamental importance to the virus to ensure successful generation of progeny virions. Throughout
the virus replication cycle, vRNAs encounter multiple potentially destabilizing host cell pathways
and processes, from regulated mRNA decay pathways to interferon (IFN)-induced vRNA decay.
Members of the Picornaviridae family are small, positive-sense single-stranded RNA viruses that have
evolved strategies to re-purpose, inhibit, or otherwise evade many components of the cellular RNA
decay machinery.
As a family, picornaviruses are composed of at least 29 different genera which include many
significant human and animal pathogens causing a range of illnesses and economic burden. The
Enterovirus genus of picornaviruses includes the causative agents of paralytic poliomyelitis (poliovirus),
hand, foot, and mouth disease (coxsackievirus (CVA) A16 and enterovirus (EV) 71), and the common
cold (human rhinovirus (HRV)). Other severe symptoms of EV infection include meningitis, encephalitis,
myocarditis, and pericarditis, which can arise from infection by subtypes of CVA, coxsackievirus B
(CVB), EV, or echovirus. The lone member of the Hepatovirus genus, hepatitis A virus (HAV), infects the
liver and, in rare cases, causes acute liver failure. The Cardiovirus genus includes encephalomyocarditis
virus (EMCV), Theiler’s murine encephalomyelitis virus (TMEV), and Saffold virus (SAFV). EMCV and
TMEV are largely non-human pathogens that cause symptoms that include myocarditis, encephalitis,
and, for EMCV specifically, reproductive failure in pigs. SAFV is a recently discovered human
cardiovirus that does not yet have clearly defined pathological features but has been linked to acute
flaccid paralysis, meningitis, and cerebellitis. Foot-and-mouth disease virus (FMDV), a member of
the Aphthovirus genus, is one of the most economically important livestock viruses. Infection by
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FMDV causes painful vesicles in the feet, mouth, and teats of cloven-hoofed animals, reducing their
productivity and requiring significant eradication measures.
Picornaviruses induce extensive modification of cellular processes to complete their replication
cycle. Upon attachment and release of genomic RNA into the cytoplasm of a host cell, viral proteins are
translated by a cap-independent mechanism using an internal ribosome entry site (IRES) located in the 5′
non-coding region (5′ NCR) of the vRNA. Picornavirus genomic RNAs are linked to a small, virus-derived
protein at their 5′ termini (VPg), possess a 3′ poly(A) tract, and encode a single open reading frame
that is translated into one polyprotein. Viral proteinases process the viral polyprotein into precursor
and mature proteins, resulting in the formation of four structural proteins and seven to eight mature
non-structural proteins, depending on the virus. Viral proteins induce membrane rearrangements to form
replication complexes, which are sites for RNA synthesis by the vRNA-dependent RNA polymerase,
3D. Newly synthesized RNAs undergo further rounds of translation/replication or become packaged
into progeny virions. To redirect host resources toward virus replication, many picornaviruses rapidly
shut down cap-dependent translation and disrupt nucleocytoplasmic trafficking to relocalize nuclear
factors required for replication into the cytoplasm [1]. Modification of the cellular landscape is largely
accomplished through the actions of non-structural proteins, particularly the viral proteinases 2A, 3C,
and L (L is encoded by FMDV) [2,3].
Picornaviruses encounter multiple cellular processes that destabilize vRNA (Figure 1). Given their
cytoplasmic replication cycle, picornaviruses avoid nuclear RNA surveillance mechanisms but
instead are susceptible to mRNA decay pathways that function in the cytoplasm, such as adenylate
uridylate-rich element (ARE)-mediated mRNA decay (AMD). Generally, mRNA decay is initiated
by deadenylation of the targeted transcript, followed by 5′→3′ or 3′→5′ degradation of the body
of the mRNA by exonucleases. To ensure that vRNAs are not targeted by mRNA decay machinery,
picornaviruses disrupt these processes at multiple levels. The strategies that picornaviruses employ to
disrupt this antiviral response have been researched more extensively than picornavirus involvement
in mRNA decay pathways. This review highlights research focused on picornavirus interactions
with pathways or processes associated with RNA decay, largely focusing on EVs, for which the most
experimental evidence exists.
Figure 1. Poliovirus interactions with host RNA decay pathways. Picornavirus RNAs are exposed to
degradation machinery from multiple RNA decay pathways and processes including 5′→3′ degradation
in processing bodies (PBs), 5′→3′ or 3′→5′ degradation by mRNA decay pathways, and endonucleolytic
cleavage as a result of activation of the innate immune response or microRNA-mediated decay.
Poliovirus RNA serves as a model for the picornavirus genome. Genomic RNA is linked to a small
virus-encoded protein, VPg, at the 5′ terminus. The 5′ non-coding region (NCR) contains a cloverleaf
structure (CL) and an internal ribosome entry site (IRES). A single open reading frame codes both
structural (VP1-4) and non-structural (2A-3D) proteins that are proteolytically processed into precursor
and mature viral proteins. The 3′ end of the genome encodes a 3′ NCR and poly(A) tract.
50
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2. Genome Stabilizing Features for Picornaviruses
Picornavirus RNAs have acquired several stabilizing features as a form of protection from cellular
RNA decay machinery. At the 5′ end of the genome, the first barrier to decay machinery is a
small, virus-encoded protein covalently bound to the 5′ terminal nucleotide of the vRNA, called
VPg (Viral Protein, genome-linked) [4,5]. VPg is used by the vRNA polymerase, 3D, as a protein primer
for RNA synthesis, resulting in vRNAs linked to VPg instead of a 7-methylguanosine (m7G) mRNA
cap. Lacking a m7G cap, picornavirus RNAs are protected from cellular decapping enzymes like
Dcp1 and Dcp2, whose activity initiates 5′→3′ RNA degradation. While cellular decapping enzymes
are unable to hydrolyze the VPg-RNA bond, a cellular 5′-tyrosyl-DNA phosphodiesterase, TDP2,
is capable of cleaving this bond and “unlinking” VPg from vRNA [6]. Cleavage of VPg may not
result in destabilization of vRNAs since unlinked vRNA has been found to be associated with actively
translating ribosomes and therefore protected from degradation, although the stability of unlinked
vRNA has not yet been measured [7–9]. As an additional protection, the major 5′→3′ exonuclease,
Xrn1, is degraded during poliovirus infection, preventing 5′→3′ digestion of unlinked vRNAs [10]
(discussed further in Section 5).
For some picornaviruses, vRNA can inhibit endonucleolytic cleavage directly through association
with ribonuclease L, (RNase L). RNase L activity is stimulated by the IFN response and contributes
to the cellular defense against infection by degrading vRNA [11] (discussed further in Section 3).
The antiviral activity of RNase L has been demonstrated for picornaviruses including EMCV and
CVB4 [12,13]. However, poliovirus RNA is resistant to cleavage by RNase L through a structured RNA
element located in the 3C proteinase coding sequence. This structured RNA binds the endoribonuclease
domain of RNase L, which inhibits its activity [14]. This RNA element is conserved in group C EVs,
which include poliovirus and several types of CVA, among others [15,16]. The element is not present
in group A, B, or D EVs, of which CVB3 is a member and was found to be sensitive to RNase L.
The protection of this RNA element from RNase L activity is not complete, however, as it was
discovered that RNase L is still capable of cleaving the poliovirus genome at distinct locations [17].
Picornavirus RNA is stabilized through association with specific host proteins. Poly(rC)-binding
protein 2 (PCBP2), an RNA-binding protein involved in mRNA stability and translation, binds 5′
stem-loop structures in poliovirus RNA to promote genomic RNA stability, viral translation, and
RNA replication [18–20]. Mutation of one of these stem-loop structures to prevent PCBP2 binding
results in diminished ability to form polysomes on poliovirus RNA, rendering the RNA susceptible
to degradation [21,22]. PCBP2 also binds the 5′ NCR of CVB3, EV71 and HRV RNA to promote viral
translation and RNA replication, but it has not yet been determined if this interaction affects vRNA
stability [23–26]. Human antigen R (HuR) is a well-characterized mRNA stabilizing protein that was
recently found to bind the EV71 5′ NCR and act as a positive regulator of translation [27]. While the
effect of HuR on vRNA stability has yet to be determined, HuR may have a similar stabilizing effect as
PCBP2, whereby promoting translation of vRNA protects it from degradation. HuR was previously
shown to stabilize genomic RNAs of togaviruses, another family of positive-sense RNA viruses [28].
HuR was also identified as a poliovirus RNA-binding protein using thiouracil cross-linking mass
spectrometry (TUX-MS), suggesting that it may have a similar effect on other vRNAs [29]. Host factors
that promote picornavirus RNA stability have not been well studied, but it is likely that many of the
proteins re-purposed for translation and replication serve a dual purpose in promoting vRNA stability.
3. Interferon (IFN)-Induced Viral RNA (vRNA) Degradation
The earliest defense against virus infection of cells involves activation of the innate immune
response, which results in expression of genes that interfere with virus replication, prevent spread
to neighboring cells, and trigger the adaptive immune response. Briefly described, detection of
pathogen-associated molecular patterns (PAMPs) by cellular pattern recognition receptors (PRRs)
initiates the innate immune response. During picornavirus infections, double-stranded RNAs (dsRNAs)
that form during vRNA replication serve as the PAMP that is recognized by a PRR. PRR bound to
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viral dsRNA transduces the signal that a viral pathogen has been detected through multiple pathways,
leading to the activation of transcription factors which promote the expression of IFN-β. IFN-β
production ultimately results in transcription of hundreds of IFN-stimulated genes (ISGs) which
collectively contribute to an antiviral state [30,31].
The IFN response activates multiple pathways to inhibit virus replication, including degradation
of vRNA by RNase L. RNase L is normally expressed in mammalian cells, but remains inactive until
infection is detected, resulting in ISG expression. Oligoadenylate synthetase (OAS) is an ISG that
activates RNase L by generating 2′-5′ oligoadenylates (2-5A), the secondary messenger that induces
dimerization and activation of RNase L [11,32]. Some picornaviruses have evolved mechanisms to
directly inhibit RNase L activity. As noted above, RNase L can be directly inhibited by binding to
a structured element within the RNA of group C EVs. Additionally, the TMEV L* protein has been
shown to bind and inhibit RNase L [33]. The L* protein is an alternative, smaller form of L generated by
leaky ribosome scanning [34]. In an uninfected cell, RNase L is inhibited by the cellular protein known
as RNase L inhibitor/ATP-binding cassette, sub-family E member 1 (RLI/ABCE). EMCV infection
induces RLI/ABCE expression, which contributes to RNase L inhibition [35]. It is not known whether
other picornaviruses induce RLI/ABCE expression as well.
Several strategies are employed by picornaviruses to prevent endonucleolytic cleavage by RNase L
prior to the nuclease becoming active. Melanoma differentiation-associated gene 5 (MDA5) is the PRR
responsible for detecting the replicative form of picornavirus RNAs [36–42]. To avoid detection, MDA5
is cleaved or degraded during infection by poliovirus, CVB3, EV71, EMCV, or HRV1a. For poliovirus,
CVB3, and EV71, the 2A proteinase appears to be responsible for cleaving MDA5; however, conflicting
reports also indicate that cleavage may occur in a proteasome- or caspase-dependent manner [39,43,44].
Interestingly, MDA5 degradation is not common to all picornavirus infections, as MDA5 remains intact
during HRV16 or echovirus type 1 infection [44]. Ligand-bound MDA5 assembles with the adaptor
molecule mitochondrial antiviral signaling protein (MAVS) at the mitochondrial membrane to transfer
the signal downstream. Accordingly, MAVS is also targeted for inhibition during viral infection. MAVS
proteolysis has been observed during infection by poliovirus, CVB3, EV71, HRV1a, or HAV [43,45–47].
Several lines of evidence point toward MAVS cleavage by the 2A and/or 3C proteinases, as well as
by caspases. In one study, expression of poliovirus, CVB3, or EV71 2A proteinase alone resulted in
MDA5 and MAVS cleavage similar to what is observed during infection [43]. FMDV infection also
results in reduction of MAVS, but not through its cleavage. Instead, the non-structural protein, 3A,
and structural protein, VP3, have both been shown to down-regulate MAVS mRNA expression [48,49].
IFN-β expression is induced following recruitment of signaling molecules to MAVS which
activates TANK-binding kinase 1 (TBK1), resulting in phosphorylation of the transcription factors IFN
regulatory factor 3 and 7 (IRF-3 and -7). Phosphorylated IRF-3/7 proteins translocate to the nucleus to
activate transcription of IFN-β. EV71 3C proteinase cleaves IRF-7, inhibiting its ability to transactivate
IFN-β expression [50]. FMDV employs a different strategy to inhibit IFN-β expression. The FMDV Lb
protein (generated by leaky ribosome scanning, similar to L*) deubiquitinates TBK1 and the signaling
molecule TNF receptor-associated factor 3 (TRAF3), thereby inhibiting their activity [51]. In addition,
the FMDV L protein causes a decrease in IRF-3/7 mRNA levels [52].
MAVS also activates proinflammatory cytokine expression by the nuclear factor-κB (NFκB)
transcription factor. NFκB activation requires phosphorylation of the NFκB inhibitor-α (IκBα) by the
IκB kinase complex, IKK (composed of IKKα, IKKβ, IKKγ). Phosphorylation of IκBα releases NFκB,
allowing it to translocate to the nucleus and activate transcription. Various strategies are employed
by picornaviruses to inhibit NFκB activation. Poliovirus, CVA16, CVB3 and EV71 2C proteins have
been shown to inhibit phosphorylation and activation of IKK by recruiting protein phosphatase 1
(PP1) to IKKβ [53,54]. FMDV inhibits IKK through cleavage of IKKγ by 3C proteinase [55]. NFκB is
also targeted directly through its p65/RelA subunit. Poliovirus, HRV14, echovirus type 1, and FMDV
cleave p65/RelA during infection [56,57] and the EV71 2C protein has also been shown to inhibit NFκB
by binding to p65/RelA [58].
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Picornaviruses antagonize the innate immune response at many steps in the pathway, including
steps not mentioned here (Figure 2). From preventing detection by vRNA sensors to inhibition and
degradation of signal transduction molecules and transcription factors, picornaviruses employ a
number of strategies to inhibit the antiviral response. Inhibition of this response promotes picornavirus
replication and spread, in part by preventing the activation of RNase L, which poses a significant
threat to vRNA stability.
Figure 2. Inhibition of ribonuclease L (RNase L) activation by picornavirus proteins. RNase L is an
effector molecule of the innate immune response. In its active form, RNase L endonucleolytically
cleaves viral RNA (vRNA). Several picornaviruses have been shown to inhibit RNase L directly through
binding of a viral inhibitor to RNase L or up-regulation of the cellular RNase L inhibitor, RLI/ABCE.
Picornaviruses also indirectly prevent activation of RNase L through extensive disruption of pathways
that contribute to the innate immune response. The signaling cascade that is initiated by MDA5
following detection of viral double-stranded RNA is disrupted at multiple steps during infection, which
prevents expression of interferon (IFN)-induced genes and activation of RNase L. Additionally, the
disassembly of stress granules (SGs) during infection inhibits SG-mediated enhancement of the innate
immune response. Simplified pathways are depicted here, highlighting points in the pathway that are
inhibited by specific picornaviruses and the viral protein responsible (“?” indicates that the viral protein
responsible is unknown). PV, poliovirus; CVA16, coxsackievirus A16; CVB3, coxsackievirus B3; EV71,
enterovirus 71; Echo 1, echovirus type 1; HRV1a, human rhinovirus 1a; EMCV, encephalomyocarditis
virus; Mengo, mengovirus (a strain of EMCV); TMEV, Theiler’s murine encephalomyelitis virus; SAFV,
Saffold virus; HAV, hepatitis A virus; FMDV, foot-and-mouth disease virus.
4. Stress Granules (SGs)
Stress granules (SGs) are a type of cytoplasmic RNA granule that contain non-translating mRNAs
and form in response to cellular stress and inhibition of translation [59–61]. Unlike processing bodies
(PBs), which are RNA granules enriched for mRNA decay proteins, SGs contain many translation
initiation factors and form around stalled translation initiation complexes [60,62–64]. SGs can assemble
and disassemble continuously and may act as sites for mRNA storage and sorting between a repressed
state, active translation on polysomes, or degradation in PBs [65–67]. Several mRNA decay factors
associate with SGs, including the Xrn1 exonuclease [63], PMR1 endonuclease [68], and the mRNA
decay proteins tristetraprolin (TTP), butyrate response factor 1 (BRF-1), and K homology-type
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splicing-regulatory protein (KSRP, also known as FBP2) [69,70]; however, SGs likely do not contribute
to mRNA decay directly, but instead they promote degradation through their interaction with PBs.
SGs and PBs can physically associate, share several protein components, and have been proposed
to exchange “cargo,” thereby targeting translationally repressed mRNAs for degradation [63,71].
Conversely, SGs are also thought to stabilize non-translating mRNAs by temporarily sequestering
them away from components of the decay machinery [72,73]. In the context of viral infection, the major
contribution to the destabilization of vRNA by SGs may be through enhancement of the innate
immune response.
Several picornaviruses have been shown to transiently induce the formation of SGs early in
infection, which disperse at roughly middle to late times during infection. The transient induction of SGs
has been visualized by immunofluorescence for the EVs poliovirus [60,74,75], CVB3 [76], and EV71 [77],
and cardioviruses EMCV [78] and TMEV [79]. During poliovirus infection, some virus-induced SGs
are compositionally unique from stress-induced SGs, containing the splicing factor and viral IRES
transacting factor (ITAF), SRSF3 (SRp20) [80]. A driving force behind picornavirus-induced SG formation
is the shut-down of host cap-dependent translation. This leads to the accumulation of stalled translation
initiation complexes which induce the aggregation of SGs. For that reason, expression of poliovirus,
CVB3, or EV71 2A proteinases alone, which cleave the cap-binding complex component eIF4G, can
induce SG formation [76,77,81].
Assembly of SGs is mediated by the SG-nucleating proteins Ras-Gap SH3 domain-binding protein 1
and 2 (G3BP1 and G3BP2) and T-cell-restricted intracellular antigen 1 (TIA-1), among others [82–84].
For poliovirus, CVB3, and EMCV, the disassembly of SGs occurs as a result of G3BP1 cleavage by
3C proteinase [74,76,78]. Expression of uncleavable G3BP1 prevents the disassembly of SGs during
infection, highlighting the importance of 3C cleavage in disrupting virus-induced SGs [76,78]. TIA-1 and
G3BP2 remain intact during infection, although that does not exclude cleavage of other SG-nucleating
proteins from contributing to the disruption of SGs. Interestingly, G3BP1 cleavage does not contribute
to the disassembly of SGs formed following infection by TMEV, which is in contrast to EMCV. Instead,
TMEV-induced SGs are inhibited by the L protein through an unknown mechanism. The SAFV and
mengovirus L proteins are also capable of inhibiting SGs when expressed in place of TMEV L [79].
Other viral proteins may also contribute to the inhibition of SGs. Expression of the poliovirus structural
protein-coding region P1, 2A proteinase, or 3A alone modestly inhibited SGs induced by oxidative
stress, although it is not understood whether these proteins play a part in inhibition of virus-induced
SGs [81].
Picornavirus-induced SGs have previously been implicated in activation of the IFN response,
but until recently it was not known how direct activation occurs. SGs induced by influenza A virus
infection, a (−) ssRNA virus from the Orthomyxoviridae family, contain vRNA and several antiviral
proteins including the vRNA sensors RIG-I and MDA5, along with OAS and RNase L. Formation
of these antiviral SGs parallel, and potentially activate, the IFN response and concentrate vRNA
in proximity to RNase L [85]. Similarly, transient SGs formed during EMCV infection were also
associated with an antiviral effect. Expression of uncleavable G3BP1 prior to infection, which prevents
the disassembly of virus-induced SGs, resulted in significantly increased levels of IFN-β and other
cytokines, as well as decreased virus replication [78]. SGs induced by the overexpression of G3BP1
inhibit the replication of CVB3, CVB5, and EV70 and contain proteins involved in the innate immune
response, such as OAS2, RNase L, and double-stranded RNA-dependent protein kinase (PKR) [86].
These data indicate that a link exists between SGs, G3BP1, and the innate immune response.
Recent investigations have revealed that G3BP1 directly stimulates the antiviral response through
recruitment of PKR to SGs. It was shown that G3BP1 directly binds PKR in SGs during mengovirus
infection, and in complex with another SG nucleating protein, Caprin1, activates PKR [87]. Active
PKR then moves into the cytoplasm, where it can mediate the innate immune response through both
its kinase activity and role as an adaptor protein. PKR induces IFN expression through activation
of the transcription factor NFκB. PKR activation of NFκB has been shown to occur through indirect
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phosphorylation of the NFκB inhibitor IκB, which results in IκB degradation and the translocation
of NFκB to the nucleus [88,89]. Interestingly, while PKR is required for IFN-α/β induction during
EMCV and TMEV infection, it does not appear to do so through transcriptional activation, but instead
through regulation of IFN mRNA integrity. EMCV infection of PKR−/− mouse cells resulted in very
little IFN-β protein production despite normal IFN-β mRNA levels. Even though IFN-β mRNA levels
appeared normal, the mRNA lacked a poly(A) tract, which resulted in its decreased translation [90].
Given a similar localization of PKR to EV-induced SGs, it would be reasonable to assume that PKR
is activated in SGs formed by other picornaviruses, thereby enhancing the IFN response to infection.
Even though RNase L was identified as a component of SGs formed following infection by CVB3,
CVB5, or EV70, it is unlikely that this localization adds to the degradation of vRNA [87]. The proximity
of RNase L to influenza A virus RNA in SGs was suggested as a possible mechanism for inhibition of
virus replication; however, picornavirus RNA has not been detected in SGs, which has been tested for
poliovirus, CVB3, and TMEV [75,76,79]. Therefore, any contribution of virus-induced SGs to vRNA
decay can most likely be attributed to the induction of IFNs, which results in activation of RNase L
and degradation of vRNA. The disassembly of SGs during picornavirus infection plays an important
part of maintaining vRNA stability through suppression of IFN-induced RNA decay (Figure 2).
5. Processing Bodies (PBs)
PBs are constitutively expressed cytoplasmic RNA granules which are composed of
non-translating mRNAs and many proteins, including those involved in mRNA decay such as
decapping components (Dcp1, Dcp2, Lsm1-7), 5′→3′ exonuclease (Xrn1), and deadenylation factors
(Pan2, Pan3, Ccr4, Caf1, poly(A) RNase (PARN)) [63,91–94]. Due to the concentration of mRNA decay
machinery in PBs, these granules have been proposed to be involved in 5′→3′ mRNA decay [93,95].
However, nonsense-mediated decay (NMD) and AMD have both been shown to occur in the absence
of PB formation despite localization of NMD or AMD proteins in PBs [70,96]. This suggests that PBs
are not required for all types of mRNA decay, but may form as a consequence of mRNA degradation or
silencing and serve to enhance the process [97]. Not all mRNAs that enter PBs are degraded. mRNAs
targeted for miRNA-mediated translational repression can localize to PBs [98–100]. Upon relief of
repression, these mRNAs may leave the PB and re-enter active translation [101,102]. Given their
complex role in mRNA decay and storage, it is not surprising that picornaviruses have evolved ways
of disrupting PBs to prevent vRNAs from aggregating in these granules.
The effect of picornavirus infection on PBs has been studied for two EVs, poliovirus and CVB3.
Following infection by poliovirus or CVB3, PB foci were almost completely absent by mid-infection.
The PB proteins Dcp1a and Xrn1 are degraded during poliovirus infection. Loss of Dcp1a likely occurs
as a result of poliovirus 3C cleavage, while Xrn1 does not appear to be a target of either viral proteinase
and is instead degraded through a proteasome-dependent pathway [10]. Degradation of Xrn1 may
have an additional benefit in protecting non-VPg-linked vRNAs from digestion by this major 5′→3′
exonuclease. While cleavage and degradation of Dcp1a and Xrn1 likely contribute to PB disruption, the
near-complete dispersal of PBs suggests that these granules are targeted through multiple mechanisms.
Deadenylation of mRNA is a necessary first step for PB formation. Inhibition of active
deadenylation through the expression of dominant negative Caf1 results in almost complete disruption
of PBs. Additionally, components of the deadenylase complexes Pan2–Pan3 and Ccr4–Caf1 localize
to PBs, and siRNA-mediated knockdown of either Caf1, Ccr4, or Pan3 disrupt PB formation [94,103].
Therefore, inhibition of deadenylation presents an additional opportunity for virus-mediated
disruption of PBs. Upon examination of deadenylase components following poliovirus infection,
it was discovered that Pan3 is degraded, possibly as result of 3C cleavage, while PARN, Pan2, Ccr4,
and Caf1 remain intact [10]. Knockdown of Pan3 has been shown to block PB formation but does not
impair deadenylation of mRNAs [94]. Thus, poliovirus-mediated degradation of Pan3 may contribute
to the disruption of PBs by preventing the association or nucleation of PB components, not through
blocking deadenylation.
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Several poliovirus proteins promote the dispersal of PBs when expressed individually, although
the mechanisms for disruption remain unclear. Expression of either the 2A or 3C proteinases alone
significantly reduced the number of PBs formed per cell, with 2A having a more pronounced effect
than 3C. Additionally, expression of either 3CD (a precursor of 3C that also possesses proteinase
activity) or the vRNA polymerase, 3D, induced a modest reduction in PBs, although their molecular
targets are unknown. The dispersal of PBs by 2A or 3C appears to occur through different mechanisms.
Expression of 2A could neither prevent the formation of stress-induced PBs nor disrupt PBs containing
exogenously expressed Dcp1a, while 3C could do both [81]. These data emphasize the importance of
the disassembly and prevention of formation of PBs during poliovirus and CVB3 infection, a process
that likely extends to other picornaviruses. The disruption of PBs highlights the significance of this
process in the virus life cycle (Figure 3).
Figure 3. Inhibition of PBs and mRNA decay proteins during picornavirus infection. Deadenylation,
decapping, and 5′→3′ RNA degradation machinery are targeted during poliovirus (PV) and
coxsackievirus B3 (CVB3) infection. The localization of non-translating RNAs and mRNA decay
proteins in PBs indicate that these RNA granules may be involved in 5′→3′ mRNA decay. PBs are
dispersed during poliovirus and CVB3 infection, thereby disrupting their possible contribution to
vRNA degradation. During poliovirus infection, Pan3 and Dcp1a are cleaved by 3C proteinase and
Xrn1 is degraded by a proteasome-dependent mechanism.
6. Adenylate Uridylate-Rich Element (ARE)-Mediated mRNA Decay (AMD)
Regulation of mRNA stability and turnover is a critical component of post-transcriptional gene
expression. Both cis- and trans-acting elements participate in regulating the stability of mRNA. Many
mRNAs encode AREs, which are sequences often found within the 3′ UTR that regulate mRNA
stability through their association with the approximately 20 identified ARE-binding proteins (AUBPs).
Stabilization or degradation of a transcript depends on which AUBPs are bound. Several AUBPs have
been well characterized for promoting AMD of target transcripts: ARE/poly(U)-binding/degradation
factor 1 (AUF1), KSRP, TTP, and BRF-1/2. Other AUBPs are better known for either stabilizing
(HuR, HuD) or repressing the translation (TIA-1, TIAR) of target transcripts [104].
AMD occurs in the cell cytoplasm and is initiated by deadenylase digestion of the 3′ poly(A)
tract, followed by degradation of the body of the mRNA using both 3′→5′ and 5′→3′ exonucleolytic
pathways [105–108]. Several decay-promoting AUBPs have been shown to directly interact with
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components of the RNA degradation machinery, suggesting a mechanism for their initiation of mRNA
decay [109,110]. It seems plausible that binding of certain AUBPs to vRNA could lead to recruitment
of RNA degradation machinery and subsequent decay of vRNA. If so, then AMD could present an
additional antiviral strategy utilized by the cell. To date, two AUBPs known for promoting AMD,
AUF1 and KSRP, have been characterized for their roles in the picornavirus life cycle. Both proteins
are shown to have a negative impact on virus replication, but apparently not through their expected
functions in promoting RNA decay.
AUF1 (also known as hnRNP D) is one of the best-described AUBPs involved in AMD and has
been shown to promote the decay of mRNAs encoding oncogenic, inflammatory, and cell cycle proteins,
among others [111–114]. In addition to its role in promoting mRNA decay, AUF1 has also been shown
to stabilize [115,116] and promote the translation of targeted transcripts [117]. AUF1 is expressed as
four different isoforms generated through alternative pre-mRNA splicing, named p37, p40, p42, and
p45 based on their apparent molecular weights [118]. All of the AUF1 protein isoforms are composed
of the same two, non-identical RNA recognition motifs (RRMs) and a glutamine-rich domain, but
display different affinities for ARE substrates and subcellular localization [119,120]. The two largest
isoforms of AUF1, p42 and p45, localize primarily to the nucleus, while the smaller p37 and p40
isoforms are predominantly nuclear, but transit between the nucleus and cytoplasm [121].
A large-scale identification of AUF1 target transcripts using photoactivatable
ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) revealed that AUF1
isoforms bind over 3000 mRNAs as well as many non-coding RNAs (ncRNAs) [122]. Pairing PAR-CLIP
with RNA-seq and polysome analysis following AUF1 overexpression implicated AUF1 in a range of
regulatory events including stabilization and destabilization of both mRNA and ncRNA, promotion and
repression of translation, and modulation of alternative splicing. In addition, AUF1 has recently been
shown to have a role in the life cycle of DNA and RNA viruses including Epstein-Barr virus [123,124],
HIV [125], hepatitis C virus [126], West Nile virus [127,128], and several picornaviruses [129–132].
A direct interaction between AUF1 and picornavirus RNA was originally discovered from an RNA
affinity screen using the 5′ NCR of poliovirus RNA [133]. This finding was later expanded to include
binding to HRV, CVB3, and EV71 RNA [129,132,133]. It was subsequently discovered that AUF1
knockout or knockdown in human or mouse cells resulted in increased replication of these viruses,
suggesting that AUF1 may act as a host restriction factor to EV infection [129–132]. Prior to these
discoveries, a study of HRV-16 infection of human airway epithelial cells reported the observation
that cytoplasmic levels of AUF1 increased during infection [134]. Cytoplasmic relocalization of
AUF1 was also observed following poliovirus, HRV-14, CVB3, EV71, or EMCV infection of human
cells [129–132]. For two of the viruses studied, poliovirus and CVB3, AUF1 was shown to relocalize
as a result of the disruption of nuclear-cytoplasmic trafficking by the viral 2A proteinase [129,131].
Given the cytoplasmic life cycle of these viruses, relocalization of AUF1 to the cytoplasm may contribute
significantly to its negative impact on virus replication.
Most reports aimed at determining the mechanism by which AUF1 acts as a restriction factor point
toward a negative regulation of viral IRES-driven translation. The interaction of AUF1 with the 5′ NCR
of vRNA has been demonstrated for poliovirus, HRV, and EV71, and this interaction was narrowed to
sites within the poliovirus and EV71 IRES [129,132]. Using in vitro translation or bicistronic reporter
assays, AUF1 was shown to negatively regulate both poliovirus and EV71 translation, likely through a
direct interaction with the viral IRES [129,132]. For EV71, it was shown that the negative effect of AUF1
on viral translation may be a result of competitive binding to the viral IRES with a known ITAF and
AUBP, hnRNP A1 [132,135,136]. hnRNP A1 also acts as an ITAF for HRV-2, but opposing regulation
by hnRNP A1 and AUF1 has not yet been investigated for this virus [137]. An additional study has
suggested that AUF1 may play a role in destabilizing CVB3 RNA. It was shown that AUF1 can bind
directly to the CVB3 3′ NCR and that knockdown of AUF1 leads to increased stability of a CVB3 3′
NCR reporter construct [131]. Whether AUF1 promotes the decay of genomic CVB3 RNA has not yet
been determined.
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Like many host restriction factors, AUF1 is cleaved during infection. For poliovirus, HRV,
and CVB3, AUF1 is cleaved by the 3C (and precursor 3CD) viral proteinase [131,133]. Cleavage of
AUF1 by poliovirus 3CD proteinase, at a site within the N-terminal dimerization domain, reduces
its ability to bind the 5′ NCR, which suggests that this process may act as a virus defense against
AUF1 [129]. Interestingly, during EMCV infection of mouse cells, AUF1 did not have a negative
impact on virus replication and remained uncleaved throughout infection [130]. Overall, these findings
support the idea that AUF1 cleavage by viral proteinases ameliorates its negative effect on virus
replication. However, many of the experiments demonstrating the negative effect of AUF1 on EV
replication were performed using AUF1 knockout or knockdown cell lines. While a direct association
with vRNA has been shown for several EVs, there may be additional indirect contributions to the
negative effect of AUF1 resulting from the dysregulation of AUF1 target mRNA and ncRNA.
Similar to AUF1, KSRP is another AUBP that has been best characterized for its role in
promoting AMD of target transcripts. Additional roles in transcription, alternative splicing, and
miRNA maturation have also been described for KSRP [109,138–140]. Like AUF1, KSRP was identified
in an RNA affinity screen for its association with vRNA; in this case, as a novel EV71 5′ NCR-binding
protein. KSRP was shown to relocalize from the nucleus to the cytoplasm during infection and to
associate with the EV71 5′ NCR, with binding occurring at multiple sites within the viral IRES. Using
protein pulse-labeling and bicistronic reporter assays, KSRP was shown to be a negative ITAF for
EV71 [141,142]. Like AUF1, KSRP is cleaved during infection. However, KSRP is not a substrate for
the viral 2A or 3C proteinases but is instead cleaved and degraded through the activity of caspases
and the proteasome and autophagy pathways [142]. KSRP has not yet been shown to act as a negative
regulator of other picornavirus infections, but it was identified as a poliovirus RNA-binding protein
using TUX-MS and thus, may have a similar effect on other EVs [29].
Other AUBPs have been shown to associate with picornavirus RNAs and participate in the
picornavirus replication cycle; however, these proteins are not typically linked to AMD. Instead, these
AUBPs are often associated with stabilization or translation of mRNA (discussed in Section 2). hnRNP
A1, the AUBP that was shown to compete with AUF1 for binding to the EV71 IRES, is a multifunctional
protein involved in transcription, alternative splicing, mRNA localization, translation, and stability [143].
hnRNP A1 has been reported to destabilize mRNAs bearing AREs [144] or an ARE-like motif (a motif
which was identified in ~7% of mRNAs) [145]. However, instead of destabilizing EV71 RNA, hnRNP
A1 is re-purposed by the virus as a positive regulator of translation [135]. Among its many functions,
hnRNP A1 has also been shown to act as an ITAF for cellular IRESs and it is this function that is utilized
to promote virus replication [135,146,147].
7. MicroRNA-Mediated Decay
MicroRNAs (miRNAs) are small, regulatory RNAs produced in eukaryotic cells that bind to
complementary sites in mRNA and act to translationally repress or signal the degradation of target
transcripts [148]. Biogenesis of miRNA begins in the nucleus, where precursor miRNAs (pre-miRNAs)
are cleaved from hairpin structures within primary miRNA transcripts by the RNase III nuclease,
Drosha [149]. Following export to the cytoplasm, pre-miRNAs are further processed to mature miRNAs
by Dicer, another RNase III nuclease [150]. Mature miRNAs are bound by a member of the Argonaute
protein family within the RNA-induced silencing complex (RISC), which together act as the effector
complex that targets complementary mRNAs for RNA interference [151].
miRNA binding can lead directly to mRNA degradation, or indirectly through degradation
of repressed mRNAs in PBs. Direct degradation of a miRNA target in animal cells is most often
initiated through recruitment of deadenylases by the RISC, and on rare occasions, by endonucleolytic
cleavage of the mRNA by Argonaute 2 (Ago2), the only catalytically active member of the Argonaute
family [148,152]. Until a few years ago, it was assumed that antiviral potential of the miRNA pathway
is not utilized during picornavirus infections, since the cytoplasmic replication cycle of these viruses
does not encounter miRNA biogenesis pathways in the nucleus. However, regions of the viral
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genome, such as the IRES, contain hairpin structures that resemble structured miRNA transcripts.
These structured regions in the vRNA provide an opportunity for the cytoplasmic miRNA machinery
to generate miRNA-like small RNAs.
Recent studies using deep sequencing techniques have revealed that viral small RNAs (vsRNAs)
are produced from HAV, EMCV and EV71 RNA in a Dicer-dependent manner [153–155]. While the
roles of the HAV and EMCV vsRNAs during infection have not been elucidated, the study of EV71
vsRNAs has revealed interesting new ways in which the virus re-purposes yet another potentially
antiviral cellular pathway. One of the EV71 vsRNAs, vsRNA-1, is derived from the second stem
loop (SL-II) of the 5′ NCR and negatively regulates viral translation and replication [155]. Instead of
inhibiting virus replication via canonical miRNA mechanisms, it was discovered that vsRNA-1 may
regulate EV71 IRES-driven translation by promoting the binding of both positive and negative ITAFs
to SL-II of the 5′ NCR. Surprisingly, vsRNA-1 recruits Ago2 to the vRNA, but instead of acting as
a negative regulator through translational repression or cleavage of vRNA, Ago2 acts as a positive
regulator of translation [27]. These data reveal the possibility for a new and interesting regulator in the
picornavirus life cycle. Whether these small, virus-derived RNAs have a negative impact on vRNA
stability similar to miRNA has yet to be determined.
8. Concluding Remarks
Picornavirus disruption of cellular RNA decay machinery generally involves a broad approach
of cleaving, degrading, inhibiting, disassembling, or re-purposing components of these processes.
However, several pathways that may contribute to vRNA instability have received relatively little
attention to date, and the focus has been on only a few members of the Picornaviridae family.
For instance, 5′→3′ RNA degradation is inhibited during infection through cleavage of decapping
enzymes and Xrn1, but it is unclear whether exosomes, which participate in 3′→5′ RNA degradation,
remain intact. There has also been little investigation into the cellular proteins that bind vRNA and
which promote vRNA stability, or conversely, promote degradation. Insight into these issues can be
provided by approaches like TUX-MS, which may reveal novel RNA-binding proteins that contribute
to vRNA stability. In addition, studying the picornavirus “cleavome,” or host proteins that are cleaved
by viral proteinases during infection, may reveal new proteins whose functions are disrupted during
infection. These cleaved proteins could include negative regulators of vRNA stability. Studies like
these will reveal not only new viral mechanisms to preserve the stability of their encoded RNAs,
but also host defense mechanisms that target vRNA for degradation.
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Abstract: The human immunodeficiency virus type-1 (HIV-1) unspliced transcript is used both as
mRNA for the synthesis of structural proteins and as the packaged genome. Given the presence
of retained introns and instability AU-rich sequences, this viral transcript is normally retained and
degraded in the nucleus of host cells unless the viral protein REV is present. As such, the stability
of the HIV-1 unspliced mRNA must be particularly controlled in the nucleus and the cytoplasm in
order to ensure proper levels of this viral mRNA for translation and viral particle formation. During
its journey, the HIV-1 unspliced mRNA assembles into highly specific messenger ribonucleoproteins
(mRNPs) containing many different host proteins, amongst which are well-known regulators of
cytoplasmic mRNA decay pathways such as up-frameshift suppressor 1 homolog (UPF1), Staufen
double-stranded RNA binding protein 1/2 (STAU1/2), or components of miRNA-induced silencing
complex (miRISC) and processing bodies (PBs). More recently, the HIV-1 unspliced mRNA was shown
to contain N6-methyladenosine (m6A), allowing the recruitment of YTH N6-methyladenosine RNA
binding protein 2 (YTHDF2), an m6A reader host protein involved in mRNA decay. Interestingly, these
host proteins involved in mRNA decay were shown to play positive roles in viral gene expression and
viral particle assembly, suggesting that HIV-1 interacts with mRNA decay components to successfully
accomplish viral replication. This review summarizes the state of the art in terms of the interactions
between HIV-1 unspliced mRNA and components of different host mRNA decay machineries.
Keywords: HIV-1 unspliced mRNA; mRNA decay; REV; UPF1; Staufen; m6A; YTHDF2
1. Introduction
Eukaryotic cells employ quality control mechanisms to ensure that each step of mRNA metabolism,
from transcription to translation and decay, is properly executed in space and time and the genetic
code is correctly expressed. mRNA surveillance and decay pathways are responsible for recognizing
aberrant mRNAs that arise due to errors in the DNA template or by misprocesses occurring during
mRNA biogenesis [1]. As such, efficient and accurate gene expression is ensured by mechanisms that
degrade mRNAs in the nucleus as a response to defects in transcription elongation [2], splicing [3],
3′-end formation [3], and nuclear export [4]. Following export to the cytoplasm, nonsense-mediated
decay (NMD), a ribosome-coupled quality control mechanism, induces degradation of mRNAs
that contain premature termination codons [5]. Other translation-dependent mechanisms of mRNA
degradation are the no-go decay (NGD) pathway, which leads to endonucleolytic cleavage of
mRNAs containing strong stalls in translation elongation [6,7], and the non-stop decay (NSD), which
corresponds to a quality control mechanism that detects mRNA molecules lacking a stop codon [8].
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In addition, some mRNAs harbor specific cis signals including miRNA target sites, AU-rich elements,
and methylated adenosines (N6-methyladenosine or m6A), which have been involved in the control of
mRNA stability [9–14].
Upon viral infection, host cells mount an antiviral stress response in order to create a hostile
environment for viral replication. This cellular response usually involves the shut-off of protein
synthesis and the concomitant assembly of RNA granules such as stress granules (SGs), which
correspond to sites of mRNA triage and PBs, which contain the mRNA degradation machinery [15].
Given the fact that most positive single-stranded RNA viruses including poliovirus (PV), hepatitis
C virus (HCV), and human immunodeficiency virus (HIV) use the same molecule first as mRNA
and then as the packaged genome, it is not surprising that these viruses have evolved different
mechanisms aimed at modulating the assembly of different RNA granules and counteracting mRNA
decay machineries [15]. Indeed, there is increasing evidence indicating that these viruses are able to
interact with and/or modify the cellular factors implicated in mRNA quality control mechanisms
during different steps of their replication cycle [15].
This review summarizes the state-of-the-art in terms of the interactions between the HIV-1
unspliced mRNA and proteins with cellular factors involved in different mRNA decay pathways.
We also discuss the potential strategies the virus has evolved to divert some of these mRNA degradation
pathways or their components and to favor viral gene expression and replication.
2. An Overview on Human Immunodeficiency Virus Type-1 (HIV-1) Gene Expression
HIV-1 is the prototype member of the Lentivirus genus of the Retroviridae family and the
etiologic agent of the acquired immunodeficiency syndrome (AIDS). The HIV-1 genome consists
of a 9 kb single-stranded RNA molecule carrying nine open reading frames that give rise to 15 viral
proteins [16]. Moreover, transcription from the 3′-long terminal repeat (LTR) promoter gives rise to an
additional protein named antisense protein (ASP), which seems to be important for HIV spread and
pandemics [17]. Once integrated into a host chromosome, HIV-1 gene expression is regulated at the
transcriptional and post-transcriptional levels by viral proteins TAT and REV, which are supported by
several host proteins [18] (Figure 1). Host RNA polymerase II drives the synthesis of the full-length
9 kb mRNA, which is identical to the genomic RNA (gRNA) present within viral particles. Early during
viral gene expression, the full-length transcript recruits the host mRNA processing machinery and
undergoes alternative splicing, generating a subset of fully spliced (2 kb) and partially spliced (4 kb)
transcripts, which in addition to the unspliced mRNA, are responsible for the synthesis of all viral
proteins [19–22]. Fully spliced transcripts (used for the synthesis of TAT, REV, and NEF) follow the
same classical gene expression pathway as cellular mRNAs, in which the rates of nuclear export and
translation are highly stimulated by the splicing-dependent recruitment of nuclear proteins including
the mRNA export factor NXF1 and the exon junction complex (EJC), amongst others (Figure 1). In sharp
contrast, partially spliced transcripts (coding for ENV, VPU, VIF, and VPR) [19,20] and the unspliced
mRNA (used for GAG and GAG–POL synthesis) [20] are not able to follow the classical mRNA nuclear
export pathway due to the presence of introns and thus rely on an alternative mechanism of nuclear
export in order to evade NXF1-associated quality controls.
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Figure 1. Post-transcriptional control of gene expression in HIV-1. Upon RNA polymerase II-driven
transcription, the capped and polyadenylated 9 kb full-length mRNA undergoes alternative splicing in
order to generate the 2 kb fully spliced and the 4 kb partially spliced (omitted for simplicity) transcripts.
Fully spliced transcripts follow the canonical pathway for mRNA metabolism, in which nuclear export
and translation are ensured by the splicing-dependent recruitment of nuclear factors such as the exon
junction complex (EJC) and the mRNA nuclear export factor NXF1. Once in the cytoplasm, fully
spliced mRNA recruits the host translational machinery in order to synthesize viral proteins TAT,
REV, and NEF and upon several rounds of translation they are degraded by the host RNA decay
machinery. The viral protein REV enters the nucleus, allowing the accumulation of the 9 kb unspliced
mRNA and its subsequent nuclear export through the chromosomal maintenance 1 (CRM1)-dependent
pathway. This alternative nuclear export pathway allows the unspliced mRNA to evade surveillance
and quality control mechanisms associated with the canonical nuclear export pathway. During its
journey to the cytoplasm, the unspliced mRNA recruits several host proteins such as up-frameshift
suppressor 1 homolog (UPF1) and the DEAD (Asp-Glu-Ala-Asp) box 3- (DDX3) RNA helicase that
will ensure an efficient association with the host translational machinery in order to synthesize the
major structural proteins GAG and GAG–POL. In contrast to fully spliced transcripts, the unspliced
mRNA does not undergo mRNA turnover as it is used as the viral genome incorporated into viral
particles. CA, capsid protein; DCP, decapping enzyme; IN, integrase; MA, matrix protein; MOV10;
Moloney leukemia virus 10; Myr, N-terminally myristoylated; NC, nucleocapsid protein; Pan2/3,
PAB-dependent poly(A)-specific ribonuclease; p6, p6 protein; Ran-GTP, ras-related nuclear protein
GTP; RT, reverse transcriptase; XRN1, 5′-3′ Exoribonuclease 1.
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3. The Full-Length and Partially Spliced mRNAs of HIV-1 Evade Nuclear Surveillance and
Quality Control Cellular Mechanisms
As mentioned above, fully spliced transcripts follow the classical gene expression pathway
employed by cellular mRNAs and are expected to undergo nucleoporin Tpr-mediated surveillance
at the nuclear pore complex [23,24]. In sharp contrast, partially spliced transcripts and the unspliced
mRNA are not able to follow the classical mRNA nuclear export pathway due to the presence of
introns, which are recognized by this NXF1-associated mRNA surveillance mechanism, which induces
nuclear retention and degradation of unprocessed transcripts [23,24]. However, the virus has evolved
the REV protein, which binds to a specific RNA structure (the REV-responsive element or RRE) present
exclusively within these intron-containing transcripts and to the host karyopherin chromosomal
maintenance 1 (CRM1) [25–27]. In addition to the leucine-rich nuclear export signal (NES) that allows
its association with CRM1, REV also possess a nuclear localization signal (NLS) that is recognized
by importins-α/β, allowing for shuttling between the nucleus and cytoplasm through nuclear pore
complexes (NPCs) [28–30].
As mentioned above, the REV protein was shown to be required for the transport of the unspliced
and partially spliced mRNAs from the nucleus to the cytoplasm by a non-canonical mRNA export
pathway [18,31]. Indeed, these intron-containing viral mRNAs are retained and degraded in the
nucleus in the absence of REV because of their incomplete splicing [32]. At the molecular level, REV
binds and oligomerizes along the 351nt RRE located within the env gene and thus is present exclusively
in all underspliced viral transcripts [33,34]. Once synthesized, REV is imported and accumulates
in the nucleus, where it binds to RRE-containing transcripts to promote their export via CRM1 [35].
It is noteworthy that the main function of CRM1 is related to the nuclear export of NES-containing
proteins and small RNAs, being only infrequently involved in cellular mRNA export [35]. As a
consequence, intron-containing viral transcripts avoid the mRNA surveillance and quality control
mechanisms associated with the canonical nuclear export pathway and accumulate in the cytoplasm
for translation [35] (Figure 1).
In addition to CRM1, a large number of cellular proteins have been shown to influence REV’s
functions in the nuclear export of unspliced and partially spliced viral mRNAs [36]. These host
factors include Matrin 3, host nuclear matrix protein (MATR3), an important host factor required
to stabilize the viral RNA through its interaction with REV/RRE [37], REV-interacting protein
(RIP)–REV/Rex activation domain-binding protein (RAB) [38,39], eukaryotic translation initiation
factor 5A (eIF5A), Src-associated substrate in mitosis of 68 kDa (Sam68), and RNA helicases such as
DEAD (Asp-Glu-Ala-Asp) box 3 (DDX3) [40], DDX1 [41], and RNA helicase A (RHA) [42], amongst
others. Whether these proteins contribute to the stabilization of the viral nuclear export of mRNP
or whether they determine the cytoplasmic fate of the viral mRNAs once exported (translation or
packaging) requires further investigation.
4. REV Stabilizes RNA Instability Elements Present within the HIV-1 Unspliced mRNA
In contrast to cytoplasmic mRNA quality control pathways such as NMD, nuclear mRNA turnover
is less understood. Interestingly, HIV-1 intron-containing mRNAs undergo nuclear downregulation
as they are further spliced to completion or degraded in the absence of REV [32,43–45]. In the late
1980s, Pavlakis´s group designed an experimental setting aimed to identify inhibitory sequences
present within the HIV-1 genome and to further study their function on viral gene expression [46–48].
They identified and characterized an inhibitory sequence in the HIV-1 gag gene that was named
INS-1 [46]. They showed that the INS-1 element does not contain any functional splice site and acts in
cis by lowering steady-state mRNA levels. Thus, INS-1 appeared to function at the level of mRNA
stability [46]. The authors suggested that the inhibitory effect of INS-1 could be overcome by the
REV–RRE interaction, demonstrating that this sequence present within the gag gene was important
for REV-regulated viral gene expression [46]. Subsequently, the same group and others described
more inhibitory sequences present in other genomic locations such as the gag/pol intersection (IN) [45],
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and within the pol (cis-repressive sequences or CRS) [49] and env [48] genes. These elements were shown
to interfere with viral gene expression by impairing mRNA stability, nucleocytoplasmic transport,
and cap-dependent translation initiation [46,50]. Interestingly, REV counteracted the defects exerted
by these mRNA instability elements, allowing efficient viral gene expression [51].
Later on, Schneider and colleagues observed that most of the regions linked to instability (INS)
contained high AU contents. Interestingly, while all REV-dependent mRNAs have unusually high
AU contents, the AU content of fully spliced mRNA species is much lower [52]. Indeed, the AU
contents within INS regions vary between 46% and 92% (with the average AU content in cellular
mRNA being around 50%). However, it has been observed that particularly unstable cellular mRNAs
such as c-myc, c-fos, c-myb, granulocyte-macrophage colony-stimulating factor, or mRNAs coding
for cytokines share unusually high AU contents, which are involved in the instability and rapid
degradation of these transcripts [53]. Interestingly, some of the viral INS elements contain the AUUUA
pentanucleotide, which corresponds to a signal (AU-rich element or ARE) known to trigger an mRNA
decay pathway known as ARE-mediated decay [53–56]. It is important to note that REV is unable to
export underspliced mRNAs that do not contain a functional INS and hence it was proposed that these
instability regions are an integral component of REV regulation [50]. Several mRNA-binding proteins,
including polypyrimidine tract-binding protein 1 (PTB)/heterogeneous nuclear ribonucleoprotein I
(hnRNP I) [57], heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) [58], and poly(A) binding
protein cytoplasmic 1 (PABPC1) [47], were shown to specifically bind to such elements in vitro. It has
been suggested that these INS-binding factors may avoid the recognition of the unspliced mRNA
by the splicing machinery and promote their association with REV, thus enabling their export and
expression. However, the precise molecular mechanisms by which INS and INS-binding factors acts
on HIV-1 gene expression are still uncertain.
Subsequently, Zolotukhin and coworkers showed that the INS region present within the HIV-1
gag mRNA was bound by the heterodimeric transcription/splicing factor p54nrb/polypyrimidine
tract-binding protein-associated splicing factor (PSF) [51]. By performing functional assays, the authors
showed that PSF subunits act at the post-transcriptional level via INS in order to inhibit gag mRNA
expression [51]. The authors proposed that p54nrb and PSF were host factors mediating INS function
through a probably novel mRNA regulatory pathway regulating HIV-1 unspliced mRNA expression.
However, a recent report showed that PSF was a positive component of the REV-mediated axis, whose
contribution was to ensure a pool of underspliced mRNAs available for REV activity [37].
More recently, Valiente-Echeverría and colleagues reported the inhibitory effect of INS-1 on HIV-1
internal ribosome entry site (IRES)-mediated translation initiation. By using heterologous bicistronic
mRNAs and both in vitro and cell-based assays, the authors showed that ectopic expression of REV
and hnRNPA1 partially rescued the inhibition of INS-1 on translation [59].
It is clear that INS and other instability sequences are cis elements important for HIV-1 RNA and
protein homeostasis and that the viral protein REV is involved in such regulation. However, it is still
unclear what molecular mechanisms are in play and thus further investigation is needed to better
understand this regulation.
5. HIV-1 Recruits Factors Involved in Cytoplasmic mRNA Decay Pathways
Cytoplasmic quality control pathways include NMD [60,61], NSD [62], and NGD [7], each of
which depends on mRNA translation. The main function of these cytoplasmic mRNA decay pathways
is to ensure the fidelity of gene expression [63,64]. As mentioned above, other pathways of cytoplasmic
mRNA decay are conditionally used to regulate gene expression of specific mRNA targets containing
specific cis-acting elements such as ARE-mediated decay [11], miRNA-mediated mRNA decay [65],
or Staufen STAU-mediated mRNA decay (SMD) [61,63,66].
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5.1. Nonsense-Mediated Decay
Nonsense-mediated mRNA decay is a quality control mechanism playing an important role in the
degradation of mRNAs harboring premature termination codons (PTCs), thus avoiding the synthesis
of truncated proteins that could be deleterious for the cell [67,68] (Figure 2). The activation of NMD
depends on the conserved function of the UPF proteins UPF1, UPF2, and UPF3 [69,70]. UPF1 has a
RNA helicase activity essential for NMD, while UPF2 serves as a bridge between UPF1 and UPF3.
UPF3 interacts with the mRNA-bound EJC components eukaryotic translation initiation factor 4A3
(eIF4AIII), Y14, and Mago homolog (MAGOH) [71,72]. It has been estimated that around 5% to 20%
of cellular mRNAs are NMD substrates, although it has not been established that every potential
NMD substrate undergoes NMD-mediated degradation [71]. As viral mRNAs associate with the
host machineries for processing, nuclear export, and translation, the question of how NMD affects
viral mRNAs arises [72]. In this regard, various reports have shown that some RNA viruses have
developed strategies to directly inhibit NMD and thus avoid this cytoplasmic mRNA degradation
mechanism [73]. Several reports have shown that HIV-1 recruits the major NMD factor UPF1 to viral
mRNPs containing the unspliced mRNA. In a pioneering report, Mouland´s group reported that UPF1
played unexpected roles in HIV-1 unspliced mRNA metabolism by promoting both nuclear export and
translation [74]. In this work, the authors showed that UPF1 knockdown resulted in a strong decrease
in HIV-1 unspliced mRNA levels and GAG expression (Figure 2a). Consistent with a positive effect
on gene expression, the authors observed that overexpression of UPF1 resulted in enhanced levels of
both the unspliced mRNA and GAG [74]. By using different mutants, the authors also demonstrated
that the role of UPF1 in HIV-1 gene expression could be separated from its functions in NMD [74].
Interestingly, Hogg and Goff reported that UPF1 was able to sense reporter RNAs bearing the HIV-1
3′-untranslated region (UTR) and trigger mRNA decay in a 3′-UTR length-dependent manner [75].
However, further analyses using the whole virus confirmed that UPF1 indeed increases the levels of
viral mRNA and the expression of GAG protein during the replication cycle [76,77]. Indeed, Mouland’s
group provided further insights into the molecular mechanism by which UPF1 regulates the fate
of the unspliced mRNA [76]. As such, Ajamian and colleagues demonstrated that UPF1 promotes
HIV-1 unspliced mRNA gene expression by forming a specific complex with REV, CRM1, and the
DEAD-box RNA helicase DDX3 [76] (Figure 2a). Interestingly, the authors also demonstrated that
UPF2 was excluded from these specific UPF1/HIV-1 mRNP [76]. Protein–protein docking suggested
that HIV-1 REV could bind UPF1 in a region that overlaps the UPF2 binding site. These in silico tests
could explain the exclusion of UPF2, which acts as a negative regulator of gene expression from the
unspliced mRNA [76]. The positive effects of UPF1 on HIV RNA metabolism reported in the context
of a full replication cycle rather than with reporter RNAs support a model in which this host protein is
not a decay-inducing factor for the HIV RNA [78].
Besides its functions on the post-transcriptional regulation of the unspliced mRNA, UPF1 was also
shown to be critical for early events of the HIV-1 replication cycle. As such, Serquiña and coworkers
reported that UPF1 knockdown or the ectopic expression of ATPase activity mutants resulted in
reduced viral entry and reverse transcription (RT) [77]. Interestingly, the authors demonstrated that
UPF1 was incorporated into viral particles through specific interactions with the nucleocapsid (NC)
domain of GAG [77].
Interestingly, RNA editing enzymes such as the APOBEC3 cytidine deaminases may promote
the generation of PTCs along the HIV RNA and thus its subsequent degradation through NMD.
Indeed, in the absence of the viral protein Vif, apolipoprotein-B-mRNA-editing enzyme catalytic
polypeptide-like 3G (APOBEC3G) generates as much as 20% of dC to dU changes by deamination
of the minus-strand during the reverse transcription process [78,79]. However, it is still unknown
whether APOBEC3-mediated hypermutations elicit NMD of the modified viral RNA.
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Figure 2. The HIV-1 unspliced mRNA has been shown to recruit components of different mRNA decay
pathways including: (a) UPF1 (NMD, nonsense-mediated decay); (b) STAU1/2 (SMD, STAU-mediated
mRNA decay); (c) RuvB-like 2 (RVB2) (NGD, No-Go decay); (d) HIV-1 trans-activating response
(TAR) RNA-binding protein (TRBP) and Argonaute (Ago) (microRNA Machinery); (e) DDX6 (PBs,
processing bodies); (f) eukaryotic elongation factor 2 (eEF2) and GTPase activating protein (GAP)
SH3 domain-binding protein 1 (G3BP1) (SGs, stress granules); and (g) YTHDF2 (N6-methyladenosine
(m6A)-dependent mRNA decay). Interestingly, most of these associations have been demonstrated to
be beneficial for viral replication, suggesting that HIV-1 has evolved mechanisms to interact with these
host factors in order to divert them from their functions in mRNA decay.
Together, these results strongly indicate that the mRNA decay factor UPF1 is critical in determining
the fate of the unspliced mRNA but also during the early steps of viral replication. The molecular
determinants that interfere with the UPF1-mediated RNA decay pathway that senses the length
of the HIV-1 3′-UTR in the context of a replication cycle are still unknown. Thus, further studies
are required to determine whether UPF1 recruitment to the HIV-1 mRNPs interferes with RNA
decay-promoting activities.
5.2. Staufen-Mediated mRNA Decay
Staufen (STAU) proteins are involved in multiple post-transcriptional regulatory processes, such as
the regulation of mRNA transport and the activation of localized mRNA translation in neurons [80,81],
as well as the binding to sequences present within the 3′-UTR of mRNAs [82,83]. Likewise, it has also
been proposed that STAU can mediate the degradation of mRNA through the interaction with UPF1 in
a process known as STAU-mediated mRNA decay [84].
STAU-mediated mRNA decay is an mRNA degradation process occurring in mammalian cells
that is mediated by the binding of Staufen to a STAU1-binding site (SBS) present within the 3′- UTR
of target mRNAs [84]. During this process, STAU1 recognizes dsRNA structures formed within the
3′-UTR of target mRNAs but also by an intermolecular association between the 3′-UTR of a target
mRNA and complementary Alu elements present in long-noncoding RNA (lncRNA). The STAU1
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paralog, STAU2, has also been reported to mediate SMD and both STAU proteins interact with UPF1,
which is a key factor required for SMD [84]. Several reports have demonstrated that HIV-1 unspliced
mRNA and GAG protein recruit STAU1 to form a specific viral mRNP (Figure 2b). By using a reporter
gene harboring the trans-activating response region (TAR) at the 5′-end, Dugré-Brisson and colleagues
presented evidence showing that STAU1 interacts with TAR, facilitating translation [85]. It was
suggested that STAU1 might facilitate the nucleo–cytoplasmic transport of transcripts containing
TAR and contribute to their interaction with the host translational machinery [85]. However, the
mechanism by which this occurs has not yet been described. In addition, Chatel-Chaix and colleagues
showed that STAU1 is an integral component of an intracellular HIV-1 ribonucleoprotein complex
containing GAG [86–88]. Furthermore, the authors demonstrated that STAU1 interacts specifically
with the NC domain of GAG in an RNA-independent manner [86]. The authors also showed that the
HIV-1 unspliced mRNA co-immunoprecipitates together with STAU1, indicating that the viral mRNA
is bound by STAU1 and the specific knockdown of STAU1 resulted in a significant reduction in viral
infectivity [86]. Later, the same research group reported the assembly of a novel STAU1 RNP whose
formation was dependent on HIV-1. STAU1, unspliced mRNA, and GAG colocalize in these STAU1
HIV-1-dependent RNPs (SHRNPs), the size of which depends on existing STAU1 levels in cells [89]
(Figure 2b).
Other studies have determined that the human protein STAU2 promotes the export of HIV-1
mRNAs containing an RRE. This effect was shown to occur through the mRNA-independent interaction
between REV and STAU2 [90]. Disruption of the REV–STAU2 interaction interferes with viral
replication, indicating that recruitment of STAU2 to the RRE (which is located at the 3′-UTR of
the unspliced mRNA) is critical for the HIV life cycle.
Together, these data strongly suggest that HIV-1 interacts with STAU proteins to form specific
viral mRNPs that are required for efficient gene expression, trafficking, and viral particle assembly. It
is unclear whether the recruitment of STAU proteins is related to a virally induced inhibition of SMD.
5.3. No-Go Decay
Recent findings suggest that HIV-1 may exploit the NGD pathway to fine-tune its own gene
expression and ensure production of infectious virions. As such, Mu and colleagues showed that
RuvB-like 2 (RVB2) inhibits HIV-1 GAG expression and that this inhibitory activity is antagonized
by the viral ENV protein [91] (Figure 2c). These authors found that the HIV-1 unspliced mRNA is
susceptible to NGD through a mechanism dependent on the translation of the matrix domain (MA)
of GAG [91]. The authors also demonstrated that the RVB2 ATPase interacts with the HIV-1 5′-UTR
and nascent MA peptides, impeding further translation of GAG or GAG–POL (Figure 2c). Thus,
it was proposed that this mechanism mediated by RVB2 allows a balance between GAG and ENV
by regulating the relative expression levels of these structural viral proteins necessary for efficient
production of infectious viral particles [91]. Thus, by using the NGD mechanism, HIV-1 exploits a host
RNA quality control pathway to maximize the quality of viral particles [91].
Together, these studies strongly suggest that HIV-1 proteins and/or RNA recruit factors involved
in the translation-dependent degradation of cellular mRNAs such as UPF1 and STAU1 in order
to ensure efficient viral replication. However, whether such interactions interfere with the mRNA
degradation processes needs to be further investigated. Thus, studies aimed at identifying other factors
that are involved in these pathways would be useful to clarify how the virus evades or interferes with
mRNA quality control mechanisms.
6. Relationship between HIV and the Cellular microRNA Machinery and Processing Bodies (PBs)
Components
RNA silencing is a mechanism for regulation of gene expression involving small non-coding
RNA [92], as well as an innate host cell defense mechanism against viruses [93]. miRNA biogenesis
begins with the RNA polymerase II-mediated transcription of miRNA precursor molecules containing a
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5′-end cap structure and a 3′-end poly(A) tail. These long primary transcripts (pri-miRNAs) are cleaved
by the Drosha–DGCR8 complex to produce 70 nt stem-loop structured precursors (pre-miRNAs), which
are exported to the cytoplasm by exportin-5 and subsequently processed by Dicer [94]. Processing of
the pre-miRNA by Dicer results in a mature miRNA guide strand that is loaded into the RNA-induced
silencing complex (RISC) containing an Argonaute (Ago) protein and other RISC cofactors to form
the microRNA-inducing silencing complex (miRISC) [94]. Mature miRISC targets specific mRNAs for
translational repression or degradation [95]. Importantly, several components related to miRISC,
such as miRNAs, mRNAs repressed by miRNAs, Ago proteins, DDX6, and Moloney leukemia
virus 10 (MOV10), together with the mRNA degradation machinery, localize in PBs [96]. In fact,
miRNA-mediated translational repression consistently correlates with mRNA accumulation in PBs [96].
One of the first works connecting HIV-1 with the cellular microRNA machinery was by Haase and
colleagues, who described the identification of HIV-1 trans-activating response RNA-binding protein
(TRBP) as a protein partner of human Dicer [97]. They showed that TRBP is required for optimal RNA
silencing mediated by siRNAs and endogenous miRNAs, most probably by facilitating the cleavage
of pre-miRNA [97] (Figure 2d). Then, Triboulet and colleagues demonstrated for the first time the
physiological role of the miRNA-silencing machinery in controlling HIV-1 replication [98]. The authors
showed that Type III RNAses Dicer and Drosha inhibited virus replication both in peripheral blood
mononuclear cells from HIV-1-infected donors and in latently infected cells [98]. In turn, HIV-1 actively
suppressed the expression of the polycistronic miRNA cluster miR-17/92, a miRNA cluster involved
in genomic amplification in malignant lymphoma and lung cancer [99–101]. This specific suppression
of the miR-17/92 cluster was found to be required for efficient viral replication and was dependent on
p300/CBP-associated factor (PCAF), a histone acetyltransferase cofactor of TAT [98].
Subsequently, Nathans and colleagues reported that HIV-1 mRNA interacts with miRISC proteins
and that disrupting PBs’ structures resulted in enhanced viral production and infectivity [95].
The authors found that HIV-1 mRNAs are susceptible to targeting by the human miRNA miR-29a,
which induces the association of viral mRNAs with miRISC. The authors also showed that miR-29a
represses viral replication by inducing an accumulation of viral mRNA in PBs [95] (Figure 2d).
Another protein component of PBs shown to be important for miRNA-mediated repression that
has been involved with the HIV replication cycle is MOV10. This protein belongs to the UPF1-like
subfamily of DExD-box RNA helicases and has ATP-dependent 5′ to 3′ directional RNA helicase
activity [102,103]. MOV10 was co-purified with APOBEC3G/A3G and shown to affect the assembly
and maturation of miRISC [104]. In 2010, Burdick and colleagues reported that MOV10 overexpression
resulted in reduced levels of both GAG protein and virus production [105]. The authors showed that
MOV10 was efficiently incorporated into virions, reducing virus infectivity, in part, by interfering with
reverse transcription [105]. In addition, MOV10 overexpression reduced the proteolytic processing
of GAG by the viral protease and the authors showed that MOV10 specifically associates with HIV-1
unspliced mRNA [105]. Curiously, these authors showed that knockdown of MOV10 decreased
virus production but showed little impact on virus infectivity, suggesting that basal levels of MOV10
are required for efficient viral replication [105]. Consistent with this last observation, Huang and
colleagues demonstrated that MOV10 potently enhances nuclear export of viral mRNAs through the
REV–RRE axis and subsequently increases the expression of GAG protein and other late products [106].
The authors also observed that MOV10 interacts with REV in an RNA-independent manner [106].
Given the discrepancies between both reports, further research is necessary to elucidate the role of
MOV10 protein during the HIV-1 replication cycle.
As mentioned above, PBs are cytoplasmic foci associated with the mRNA decay machinery
as they contain mRNA decapping enzymes (Dcp1/2) and the 5′-3′ exonuclease XRN1 [107,108],
deadenylation factors (Ccr1, Caf1, Not1) [109], NMD-associated proteins (SMG5-6-7, UPF1) [107,110],
and translational repressors (CPEB, eIF4E-T, DDX6) [111,112]. Co-localization of miRISC and target
mRNAs in PBs suggests that they function in miRNA-mediated gene silencing by sequestering target
76
Viruses 2016, 8, 320
mRNA for storage or decay [113–115]. Indeed, several PB components such as GW182 and DDX6
(RCK/p54) play important roles in miRNA-dependent translational repression [116].
Besides the interactions of HIV-1 with the miRISC machinery described above, several reports
have shown that HIV-1 co-opts some PBs components to promote viral replication. It has been reported
that depletion of Ago2 or DDX6 produces inhibition of HIV-1 replication, indicating a role of these
PBs-associated proteins in the viral life cycle [117,118]. Indeed, Reed and colleagues demonstrated that
the assembly intermediates (AIs), containing HIV-1 GAG, GAG–POL, and VIF [119], are formed by
the recruitment of DDX6 and ATP-binding cassette protein E1 (ABCE1), thus providing evidence that
HIV-1 utilizes these factors to catalyze the assembly of immature capsid intermediates [120] (Figure 2e).
Interestingly, Abrahamyan and colleagues showed a dramatic decrease of PBs around HIV-1 unspliced
mRNA-containing foci, suggesting a local dissolution of PBs close to assembly sites [89].
7. Interactions of HIV-1 and Components of RNA Granules Involved in mRNA Silencing
In response to environmental stress such as viral infection, eukaryotic cells reprogram their
translational machinery to allow the selective expression of proteins required for cell viability in the
face of changing conditions. mRNAs encoding constitutively expressed proteins are redirected from
polysomes to RNA granules during stress conditions. Two of these RNA granules have been well
characterized in yeast and mammalian cells, SGs, which correspond to translationally silent sites
of RNA storage, and PBs, which are foci involved in mRNA degradation [121]. During stress, SG
assembly signaling can be triggered by the phosphorylation of translation initiation factor eIF2α,
which reduces the availability of the eIF2–GTP–tRNAMet ternary complex necessary during translation
initiation [122,123]. Interestingly, HIV-1 replication was shown to interfere with SG assembly in favor
of the assembly of viral specific mRNP containing STAU1 [89]. More recently, Valiente-Echevería
and colleagues demonstrated that the HIV-1 GAG protein blocks SG assembly through an interaction
between the N-terminal domain (NTD) of the capsid domain and the host eukaryotic elongation factor
2 (eEF2) [124] (Figure 2f). The authors also reported that GAG could mediate the disassembly of
pre-existing SGs via an interaction with the SGs-dependency factor GTPase activating protein (GAP)
SH3 domain-binding protein 1 (G3BP1) [124]. Interestingly, the mechanism by which HIV-1 interferes
with SG assembly depends on the nature of the stressor. Indeed, the blockade of selenite-induced SGs
was dependent on activation of eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1)
and the consequent inhibition of cap-binding by eIF4E [125] (Figure 2f). More recent data showed that
G3BP1 binds the HIV-1 unspliced mRNA in the cytoplasm of macrophages to inhibit viral replication,
supporting a role for G3BP1 and probably SGs as restriction factors that must be counteracted by
HIV-1 [126].
8. Control of HIV-1 mRNA Abundance by Methylation of Viral Transcripts
Although hundreds of chemical modifications have been described in RNA, much less is known
regarding the mechanisms and functions of these marks [127]. Methylation at the N6 position
of adenosines is the most abundant internal modification identified in mRNAs and lncRNAs in
many eukaryotic species, including yeast and mammals [128]. Accumulating evidence suggests that
m6A regulates mRNA metabolism post-transcriptionally by altering the processing, nuclear export,
translation, or stability of the modified mRNA [128].
It has been known for almost 40 years that, in addition to cellular mRNA, the RNAs of the
influenza virus, adenovirus, Rous sarcoma virus (RSV), herpes simplex virus type 1 (HSV-1), and simian
virus 40 (SV40) are m6A-modified [129–133]. Although the precise impact of this modification on viral
replication still remains unclear, recent studies revealed that the presence of the m6A modification in
the HIV-1 unspliced mRNA significantly affects gene expression and viral replication [134–136].
The post-transcriptional addition of m6A to mRNAs occurs predominantly in the nucleus
and is catalyzed by a heterotrimeric protein complex consisting of two methyltransferase-like
enzymes, METTL3 and METTL14, and the cofactor Wilms’ tumor 1-associated protein (WTAP),
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which together are recognized as the “writers” of m6A [137–139]. Fat mass and obesity-associated
protein (FTO) and α-ketoglutarate-dependent dioxygenase homolog 5 (ALKBH5) are two specific m6A
RNA demethylases (“erasers” of m6A) responsible for adenosine demethylation and its associated
regulation [140,141]. The main “readers” of m6A on mRNAs are members of the so-called YTH
domain-containing family. Amongst them, the cytoplasmic YTH proteins YTHDF1, YTHDF2, and
YTHDF3, and the nuclear protein YTHDC1, have been shown to bind directly to m6A-containing
mRNAs [13,14,139,142]. Recent studies indicated that m6A binding by YTHDF1 results in enhanced
translational rates of its targets due to a specific interaction between YTHDF1 and eukaryotic initiation
factor 3 (eIF3) [13]. In contrast, binding of m6A by YTHDF2 results in both the localization of its mRNA
targets in PBs and concomitant accelerated degradation [143]. m6A-mediated mRNA degradation was
shown to occur by the interaction between YTHDF2 and the CCR4–NOT deadenylase complex [128].
The precise function of YTHDF3 is still unclear [13,14,144]. Besides the mRNA degradation induced
by binding of YTHDF2 to m6A, there is also evidence suggesting that the presence of this chemical
modification could indirectly destabilize some transcripts by preventing the binding of the mRNA
stabilizing protein human antigen R (HuR) [145]. Moreover, m6A regulates mRNA alternative splicing
both directly through the recruitment of the m6A reader YTHDC1 and indirectly by altering RNA
structures close to the binding sites of the splicing factor heterogeneous nuclear ribonucleoprotein C
(C1/C2) (hnRNPC) [142,146].
Recently, Lichinchi and colleagues reported that the HIV-1 unspliced mRNAs (and probably other
viral transcripts) contain multiple m6A modifications along their sequences [135]. Interestingly, the
authors also observed that viral infection in a CD4+ T-cell line resulted in increased m6A levels in
cellular poly(A) RNA [135]. They also showed that methylation of two conserved adenosines within
the stem loop II region of the RRE was important for binding of REV, resulting in enhanced rates of
nuclear export of the methylated viral mRNA, thus revealing the importance of the m6A modification
for nuclear export of Rev-dependent viral mRNAs [135]. Moreover, Kennedy and colleagues found
four clusters of m6A modifications in the 3′-UTR region of the HIV-1 unspliced mRNA that enhanced
viral gene expression by recruiting the three cytoplasmic m6A “readers” proteins YTHDF1, 2,
and 3 [134]. Notably, the authors observed that HIV-1 replication was dependent on the levels of
YTHDF2 expression in infected T cells. As such, the virus presented enhanced GAG synthesis and viral
particle production when YTHDF2 was overexpressed, while GAG protein and viral titers were reduced
when the YTHDF2 gene was knocked out by the clustered regularly interspaced short palindromic
repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) system [134]. Contrary to the roles
of YTHDF2 in mRNA degradation, the effects of YTHDF2 on HIV-1 replication were associated with
enhanced viral mRNA abundance. Together, these data identified m6A and the resultant recruitment
of REV or YTHDF proteins as major positive regulators of HIV-1 mRNA abundance in the cytoplasm
(Figure 2g) [134]. It is noteworthy that, similar to what has been reported for mRNA decay factors UPF1
and STAU1, these data suggest that HIV-1 uses the mRNA decay-associated m6A reader YTHDF2 to
promote viral replication.
More recently, Tirumuru and colleagues showed that proteins YTHDF1–3 recognize incoming
m6A-modified HIV-1 RNA and inhibit reverse transcription during the early steps of infection in both
cell lines and primary CD4+ T-cells. Consistent with this observation, knockdown of YTHDF1–3 in
cells resulted in enhanced reverse transcription products [136]. However, the same authors showed
that silencing m6A writers decreased HIV-1 GAG protein expression in virus-producer cells, while
silencing m6A erasers increased GAG expression. The authors concluded that m6A plays a negative
role during reverse transcription and a positive role later during viral gene expression [136].
Further research is necessary to elucidate the precise role of YTHDFs proteins, particularly
YTHDF2, during the HIV-1 replicative cycle.
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9. Conclusions and Future Perspectives
The HIV-1 unspliced mRNA plays critical roles during viral replication since it is used (i) as the
precursor mRNA molecule undergoing alternative splicing in order to generate the remaining viral
transcripts; (ii) as the mRNA template for GAG and GAG–POL synthesis; and (iii) as the genome
packaged into newly assembled viral particles.
Interestingly, this 9 kb viral transcript possesses retained introns and AU-rich sequences—both
signatures being incompatible with nuclear export and mRNA stability. In addition, the unspliced
mRNA recruits different host factors including UPF1, STAU1/2, and the recently characterized m6A
reader protein YTHDF2, all of them associated with mRNA degradation. Despite all these constraints,
HIV-1 has evolved mechanisms that ensure the presence and stability of the unspliced mRNA in the
cytoplasm of host cells. The viral protein REV appears as a key factor, not only allowing the exit of the
unspliced RNA from the nucleus by an alternative pathway and overcoming surveillance mechanisms
but also interfering with cis-acting instability RNA elements and coordinating the recruitment of
some of these mRNA decay factors that instead play positive roles in viral gene expression and virus
production. The relationship between HIV-1 mRNAs and the host mRNA decay machinery has
historically been a very poorly explored field. Whether viral proteins or the infection per se interfere
with NMD, SMD, mRNA decapping, or deadenylation has to our knowledge never been evaluated.
Further studies on this unexplored topic will help us to better understand the RNA biology behind
HIV-1 replication and will certainly contribute to the development of new and novel drugs aimed at
counteracting viral production and avoiding viral resistance.
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Abstract: Murine polyomavirus (MPyV) infects mouse cells and is highly oncogenic in
immunocompromised hosts and in other rodents. Its genome is a small, circular DNA molecule of
just over 5000 base pairs and it encodes only seven polypeptides. While seemingly simply organized,
this virus has adopted an unusual genome structure and some unusual uses of cellular quality control
pathways that, together, allow an amazingly complex and varied pattern of gene regulation. In this
review we discuss how MPyV leverages these various pathways to control its life cycle.
Keywords: quality control; transcription; RNA decay; RNA editing; nuclear retention
1. The Virus
Murine polyomavirus (MPyV) is highly oncogenic in rodents and has a small circular
double-stranded DNA (dsDNA) genome of about 5300 base pairs. The genome is divided into “early”
and “late” regions, which are expressed and regulated differently as infection proceeds (Figure 1) [1–4].
The early and late transcription units extend in opposite directions around the circular genome from
start sites near the bidirectional origin of DNA replication [2,5]. Primary RNA products from the
early transcription unit are alternatively spliced to yield four early mRNAs which encode the large T
antigen (100 kDa), the middle T antigen (56 kDa), the small T antigen (22 kDa) and the tiny T antigen
(10 kDa) [6]. Large T binds to sequences in or near the DNA replication origin region [7–10] and is
involved in the initiation of DNA replication, indirectly in the autoregulation of early-strand RNA
levels [11–13], and indirectly in the activation of high levels of expression from the late promoter [13,14].
The other early proteins are dispensable for lytic infection, but are important for cell transformation
and tumorigenesis [15]. Late primary transcripts accumulate after the onset of DNA replication and
are also spliced in alternative ways to give mRNAs which code for the three virion structural proteins
VP1, VP2 and VP3.
While seemingly simply organized, MPyV has adopted an unusual genome structure that provides
a platform for the participation of a number of cellular gene regulatory and quality control mechanisms.
First, the intergenic region is complex and crowded and serves multiple functions during infection.
Consisting of only several hundred nucleotides, this region contains the origin of bidirectional DNA
replication, the early promoter and the late promoter. Each of these is impacted by distinct molecular
machinery, competing for overlapping sequence elements. Activation of the replication origin requires
the recruitment of the cellular DNA replication machinery by large T antigen, which recognizes a
number of sites in this region. The early promoter is a typical RNA polymerase II promoter, including a
TATA box to specify early transcription start sites and an upstream enhancer region. The late promoter
is TATA-less and specifies transcripts with a multitude of 5’-ends spanning more than 100 nucleotides.
Second, the distal ends of the early and late regions are tightly connected (Figure 2) and, as we will
see below, this organization plays a major role in the regulation of the viral life cycle. The ends of
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the coding regions for large T antigen and VP1 are very close to one another, separated from each
other by only 23 base pairs. Also, the polyadenylation signals for early-strand and late-strand primary
transcripts actually overlap one another. This leads to overlapping 3′-ends of early and late mRNAs
and pre-mRNAs, with the amount of overlap being 45 base pairs or greater. As we shall discuss below,
transcript overlap appears to be essential for the viral life cycle, since viruses that are constructed to
eliminate this overlap fail to enter the late phase of infection [16]. Third, the splicing signals for late
mRNAs are arranged in a manner rarely seen in eukaryotic transcripts. In most pre-mRNA molecules,
the first splice site encountered is a donor, 5′-splice site. This allows the splicing of the first exon to the
second exon. In MPyV late transcripts, the cap-proximal splice site is actually an acceptor, 3′-splice site.
This almost unique arrangement turns out to be critical for the viral life cycle.
Figure 1. The murine polyomavirus (MPyV) genome. The genome shown is of strain NG59RA, which
is 5327 base pairs in length. Early genes are in blue and late genes are in red. Transcripts are lines,
with thicker regions denoting open reading frames and dotted lines introns. The replication origin
and transcriptional control region is shown at the top of the genome. Late-strand transcripts can give
rise to two miRNAs (small red line) that map to the early region and can influence viral and host
gene expression.
Figure 2. A crowded arrangement at the ends of the early and late genes. The sequence shown is
of the 3′-region of the early and late transcription units, with the early coding strand on top and the
stop codons for large T antigen and the virion structural protein VP1 circled. Note the overlap of
the polyadenylation signals, including the canonical AATAAA elements (yellow box). Cleavage and
polyadenylation occur downstream of these elements, leading to early and late mRNAs that have the
potential to overlap for at least 45 base pairs (bp) at their 3′-ends. Transcript overlap is essential for the
viral life cycle.
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2. The Viral Early–Late Switch
Temporal regulation of MPyV gene expression during lytic infection of permissive mouse cells
proceeds in a well-defined and tightly regulated manner [1,17,18]. Immediately after infection, RNA
from the early transcription unit begins to accumulate; however, RNA from the late transcription unit
fails to accumulate to a significant level. At 12 h after infection, the early–late RNA ratio is about 4
to 1 [1,18–20] and in the presence of DNA replication inhibitors, the ratio is 10 to 1 or even higher.
At 12–15 h post-infection, viral DNA replication commences and late-strand RNA begins to accumulate
rapidly and almost exponentially, while early-strand RNA and proteins accumulate much more slowly.
In absolute terms, the amount of early-strand RNA in the cell is similar at 12 h and 24 h post infection.
Thus, there is a dramatic change in the relative abundances of early-strand and late-strand RNAs; by
24 h post-infection, the early to late RNA ratio is as low as 1 to 50 [1,18–20]. This early–late “switch”
depends absolutely on viral DNA replication. If replication is inhibited, early mRNAs continue
to accumulate but late mRNAs fail to do so [11,12,19–22]. While it was thought in the field for a
number of years that the early–late switch is the result of T antigen repression of the early promoter,
coupled with a transactivation of the late promoter, this now seems to be incorrect. Rather, the switch
appears to result from changes in transcription elongation and/or RNA stability [13,19,23–25]. Late
RNA accumulation is regulated post-transcriptionally by what appears to be a novel RNA titration
event (late gene expression from a non-replicating viral genome can be activated in trans by sufficient
levels of late transcription from a replicating genome in the same cell) [13], while early RNA levels are
regulated at least in part by antisense RNA and RNA editing (Figure 3) [13], as well as by virus-encoded
miRNA [25] (see Figure 1).
Figure 3. The early–late switch is associated with poly(A) signal readthrough and double-stranded
RNA (dsRNA) formation. See text for details of the regulation. At early times and before viral DNA
replication (left), transcription occurs from both the early and late promoters. Early-strand RNAs are
spliced to produce mRNAs for the early proteins. Late-strand transcripts are efficiently terminated
and polyadenylated, but are unstable and produce only small amounts of late mRNAs and proteins.
After the onset of DNA replication (right), transcription termination and polyadenylation become less
efficient, allowing multigenomic transcripts to be produced. Giant transcripts are efficiently spliced
to generate stable late mRNAs, but sequences antisense to early-strand transcripts can downregulate
early genes.
Even before the onset of viral DNA replication, however, the late-strand is actually being
transcribed, but with little stable RNA accumulation. This latter phenomenon is associated with
several important genomic features. At early times after infection, polyadenylation of late-strand
transcripts is efficient. This generates RNAs that can be alternatively spliced to generate mRNAs for the
virion structural proteins VP1 and VP3. VP2 mRNA from these transcripts is unspliced. Importantly,
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however, by a mechanism that remains unclear, these RNAs appear to be inefficiently exported from
the nucleus to the cytoplasm and are degraded in the nucleus [26].
3. Late-Strand RNAs
How is late-strand gene expression enhanced at late times in infection? While at early times
late-strand polyadenylation is efficient, this changes dramatically at late times. After DNA replication
initiation, late-strand polyadenylation becomes inefficient, allowing RNA polymerase II to continue
around and around the circular genome, generating giant multigenomic transcripts. Thus, the MPyV
life cycle can be viewed as an interesting model of regulation of alternative polyadenylation,
a phenomenon that has been studied in a variety of other systems [27,28]. Most late-strand primary
transcripts are heterogeneous in size, and range from about 2.5 Kb to over 60 Kb in length [29–34]. Most
are not polyadenylated [34]. Late-strand pre-mRNA molecules are processed into mature mRNAs
using a highly unusual pathway that involves ordered splice site selection from precursors containing
tandemly repeated introns and exons [35]. The great majority of late RNA sequences never leave the
nucleus as they are removed during mRNA processing, and are subsequently degraded [30,36]. Some
of these giant transcripts may also serve as precursors for the processing of viral miRNAs, one of
which also downregulates the pro-apoptotic factor Smad2 [25,37].
The MPyV late region encodes 57-nucleotide non-coding exon near at the 5′-end of the
transcription unit. At their 5′-ends, late messages contain multiple tandem repeats of this late leader
sequence, which appears only once in the viral genome. Pre-mRNA molecules are processed by a
pathway that includes the splicing of late leader exons to each other (Figure 4). Each class of late viral
message (encoding virion structural proteins VP1, VP2 or VP3) consists of molecules with between
1 and 12 tandem leader units at the 5′-end [38], with most containing more than one. VP2 mRNA
is the least abundant late message (about 5%) and contains no leader-to-body splice. Even in the
absence of leader-to-body splicing, this message is nevertheless exported to the cytoplasm, although
inefficiently [39]. Late-strand pre-mRNA processing is highly unusual, because it involves alternative
selection between identical splice sites. Thus, in long pre-mRNAs, only the terminal coding body
3′-splice site is chosen, even though an upstream one exists in the precursors [35,38].
Figure 4. Late pre-mRNA splicing. Giant transcripts serve as precursors to late mRNAs. Processing of
VP1 mRNA is shown. In multigenomic transcripts, leader (L) exons splice to one another, removing
genome-length introns. Then, a leader-body splice can occur, coincident with polyadenylation.
This results in mRNAs with tandem non-coding late leader exons at their 5′-ends.
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While the splicing process is connected to mRNA accumulation, we hypothesize that tandem
leaders may serve the additional purpose of facilitating translation initiation owing to the fact that
leaders contain two regions with significant complementarity to the 3′-end of mouse 18S rRNA
(Figure 5). Such regions could be coincidental and there may exist numerous other regions in cellular
or viral RNAs. However, as most late MPyV mRNAs contain multiple tandem leaders in their
5′-untranslated regions (UTRs), this feature of multiple complementary sequences, preceding late
AUG codons, could serve as a powerful way to recruit ribosomes and enhance the expression of virion
structural proteins late in infection.
Figure 5. The late leader exon has regions of complementarity to 18S rRNA. While the biological
consequence of this still remains unclear, there is striking complementarity to ribosomal RNA at
two positions within the leader. We speculate that in late mRNAs containing tandem leaders in their
5′-untranslated regions (UTRs), these elements may serve to enhance the translation of late proteins.
4. Activation of Late RNA Accumulation
Late-strand gene expression may not be regulated primarily at the level of transcription initiation.
Non-replicating genomes express only very low levels of late-strand transcripts. However, late genes
from these non-replicating genomes are turned on if a replicating polyoma genome is introduced into
the same cell [13]. Further, the presence of wild type genomes in mouse cells can lead to the activation
of late genes in trans from a non-replicating genome in the same cells [13].
5. The Role of dsRNA Formation and A-To-I Editing in MPyV Gene Regulation
Due to the readthrough of early and late transcripts at late times, as well as the genomic overlap
of the early and late polyadenylation signals, there is the possibility that if complementary sequences
accumulate near one another in the nucleus, they might anneal to form double-stranded RNAs
(dsRNAs). Also, since viruses that do not allow early-strand and late-strand overlap do not undergo
productive infection and cannot enter a normal late phase [16], it is likely that dsRNA plays an
important role. Nuclear dsRNAs can be promiscuously edited by dsRNA-specific adenosine deaminase
(ADAR) enzymes, which deaminate adenosines to inosines [40]. Consistent with sense–antisense
overlap of the MPyV early and late transcripts, viral RNAs also exhibit extensive and promiscuous
editing [16,20,41,42]. During productive infection, there is a time-dependent increase in editing, with
especially efficient editing observed around the overlapping polyadenylation sites [20]. No significant
editing was detected before DNA replication or in the presence of a replication inhibitor [16,20].
Editing in the polyadenylation region has led to speculation that this editing serves as a trigger for the
early–late switch. While editing is readily and abundantly observed, however, at this time we cannot
conclude whether it is a cause or a consequence of viral gene regulation. The possibility exists that
editing is a consequence of dsRNA formation while duplex RNA formation may in fact be the primary
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event that drives the early–late switch. This is because mouse cells lacking ADAR activity have been
reported to maintain the ability to support productive MPyV infection [43].
6. Early-Strand RNAs
How is early-strand gene expression lowered at late times in infection? There appear to be
multiple mechanisms for this. While the switch from early to late phase of infection has been reported
by others to be regulated primarily at the level of transcription [44], this has been challenged by
results which are, in fact, consistent with a change in the processing of late-strand transcripts [14,19].
Inefficient late-strand polyadenylation and transcription termination appear to regulate early-strand
gene expression in an indirect manner. The long, multigenomic late-strand transcripts in the nucleus
can form RNA–RNA duplexes with early-strand transcripts which are efficient substrates for RNA
editing by ADARs. This leads to the deamination of up to 50% of the adenosines on each strand
to inosines (which act biochemically and genetically like guanosines). These promiscuously edited
RNAs are retained in the nucleus by a quality control system involving binding to the p54nrb/NONO
protein [45] and localization to nuclear bodies called paraspeckles [46,47], preventing them from being
exported to the cytoplasm and being translated into mutant proteins [45]. As late primary transcripts
accumulate to high levels in the nucleus, the opportunity for sense–antisense hybrids to form may
increase, leading to ever greater inhibition by editing. While a similar phenomenon may also occur
on the late strand (early-strand polyadenylation site readthrough, followed by dsRNA formation
and A-to-I editing), the consequences in this case are minor because the editing would occur in
genome-length introns of late pre-mRNAs rather than in late coding regions. In this manner, a cellular
quality control system that prevents the nucleocytoplasmic export of dsRNAs and promiscuously
edited RNAs plays an important role in reducing the availability of MPyV early-strand mRNAs for
translation at late times in infection when the early gene products are no longer needed.
Yet another way in which early expression changes after the onset of viral DNA replication is
at the level of transcription initiation. Through a mechanism that still remains unclear, as infection
proceeds, the 5′ transcriptional start sites from the early promoter shift progressively further and
further upstream from the canonical start site downstream of the early TATA element, which is used
almost exclusively in the absence of DNA replication [20,22,48] (Figure 6). Thus, at late times, many
early-strand mRNAs have 5′-UTRs that are hundreds of nucleotides longer than mRNAs at early times.
This shift is dependent on DNA replication but not directly on the presence of large T antigen, because
large T antigen is expressed in the presence of replication inhibitors, yet in this case the shift does not
occur [20]. What are the consequences of shifting early-strand 5′-ends? They may alter RNA stability
and therefore lead to reduced levels of mRNA. We hypothesize, however, that they serve as yet another
mechanism to limit early gene expression at late times, by leading to inefficient ribosome scanning
and translation initiation. We note that many of the early-strand mRNAs at late times contain AUG
codons that are frameshifted relative to the normal AUG codon and therefore would be poor messages
for T antigen expression. This replication-dependent switch has also been observed for several other
viruses, suggesting a more common mechanism by which small DNA viruses might limit early gene
expression late in infection. Altered early-strand start sites at late times have been reported both for
simian virus 40 (SV40) [49] and for the John Cunningham (JC) virus [50].
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Figure 6. Early-strand transcription start sites shift after the onset of viral DNA replication. (A) An
expanded view of the intergenic region is shown, along with genome browser tracks showing the
alignment of early-strand RNAs at several times after infection, as reported by us recently [20]. These
data were confirmed using the 5′-rapid amplification of cDNA ends (RACE) analysis [20]. Note the
dramatic shift from 5′-ends mapping to a specific site at early times (EE) to many upstream sites at
later times (LE); (B) The intergenic region is depicted, along with a general cartoon of early-strand
RNAs at early times (EE) and early-strand RNAs at late times (LE). Positions of large T antigen
binding are shown, along with the palindromic core replication origin, the enhancer region and the late
transcription start site region. Red stars denote AUG codons that could direct translation initiation.
Those in LE but not EE transcripts are frameshifted relative to the early coding region.
7. Conclusions
In conclusion, the mouse polyoma virus employs a variety of mechanisms to regulate the synthesis,
processing, stability and translation of its RNAs in order to optimize the timing and efficiency of its
life cycle. Taken together, the various modes of regulation adopted have given MPyV a powerful set of
strategies to ensure efficient progression through its lytic life cycle. Some of these (such as shifting
transcription start sites and promoter regulation) are shared by other viruses and systems, while others
(such as the role of leader-to-leader splicing, polyadenylation site overlap and nuclear retention of
dsRNAs and edited RNAs) are interesting and perhaps peculiar to this virus. Interestingly, while SV40
does not normally downregulate its early gene products using antisense RNA, it has been reported that
in SV40-transformed human mesothelial cells, an integrated viral genome promotes polyadenylation
site readthrough from the early region, thus generating antisense RNA that downregulates late
gene expression [51]. Further, a recent study on the Merkel cell polyomavirus (MCPyV) life cycle
presented transcriptomic data consistent with multigenomic transcripts, similar to those we see in
MPyV infection [52].
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